Filename,SciSpacy Biomarkers,BiomedNLP Biomarkers
A (1).pdf,"HC]), CEA, CRC patients, tumor, wereidentifiedasthecorecontributorstodis-, CRC cell lines SW480, ourfindingsintheproteomicscohortusingELISAintwoinde-, mor, NTA, MLdiagnosticmodelsbasedon12candidateEVpro-, SW620, EVs, cardiovascular, Figure5, TSG101, cancer, CD63, levelsofAACTintheurineofpatientswithmetastaticlungcancer","##le, crc, l, ##dingsintheproteomics, ##anda, ##elis, identifiedpf, -, mor, ev, forth, ##he, weredetermined, dia, ##gno, ##finding, and, ##pithel, aa, ##sample, ##pf, separated, openaccess, metryidentified, ##edthetoprankingpathwaysbasedonev, derived, ##aa, ##tributors, ##vity, ##pf4, ##dia, 12, ##xi, ##heev, the, ##ale, august, ##rombo, ##tha, ##ves, ml, ##gnosticmodel, ##4andaactast, of, st, ##todis - tinguis, ##ete, ##h, precision - recall curve, t, september27, ##ustrates, ##lyelev, ##ingtransmissionelectronmicroscopy, roc, ##kv, ##ial, ##evproteinsf, ##nd, ##var, ##analysis, ##mapnetworkanalysisofassoc, ##elevate, ##bar, ##erumevsmayori, ##arlydiagno, best, ##ur, ##production, ##marker, ##ctasacandidatebiomarker, ##ide, our, importanceinpro, ##methodsareprovidedintheonlineversionoft, ##hispaperand, ##performance, sequential window, tumor, ##dis, ##pro, ##ase, ##hort, ##ead, 5 different, not, ##pl, ##app, valuesbarpl, ##pf4 - high, ##e, ##ction, atedp, ##actexhibit, evsfromserumweresubjectedtosubsequentexper, ##fr, intracellu, ##play, seqanalysis, ##iablesin, confusion, ##gnosticmodelsbase, by, ##of, ##thekeyproteinsinvolved, western, ##fortheev, abnormal, ##ed, ##th, ##pleyvalues, 13ll, spectro, ##basedonev, ##tic, int, ##ct, 11ll, sc, ##the, ##icle - like, ##predictionresultsfor273testset, legend, ##rna, ##gnosticmodelsb, ##how, variable identification, ##sin, ##taactcouldalsoserveasatu -, ce, ##bot, ##crcp, ##icts, ##ins, gs, ##mation, ##edsuperiordiagnostic, ##cr, trainsetand, ##ast, ##ep, low, ##in, tsg101, june, ##nce, ##comb, ##su, ##ev - derivedpf4andaact, ##gnosticpanels, ##ces, 25, ##sp, ##otill, ##gina, ##plicate, ##ev, ##reveale, ##ef, ##otted, ##ourres, ##andcha, tracking, ##f4, nanoparticle, 37, grp9, ##apply, ##for, ##calnexinwerenotexposed, ##inseparatedevs diagnosis, cell, relateddiagnosticmodel, ##firmed, ##cellsasthema, ##jorso, vip, ##oft, enrichment, mlmodel con - validation, (, ##ac, ##case, ##mapnetwork, 2024, related, predict, ##ive, declarationof, 338, ##dt, ##aact, 98, ##leaminoacidvar, ##hepotentialinteraction, het, ##edd, lass, ##pf4 -, ##and, la, july, ##hee, ##forth, theoretical, tudysuper - limitationsofthestudy, hc, ##therf, ##ion, ##par, ##aact -, cd63, detailed, ##inating, rf, ##plasma, ##te, ##f, ##using, ##reveals, ##ested, ##her, ##rf, ##o, functional, ##ple, ##thes, ##is, ##plotted, ##tobethem, ##don12candidateevpro - theserumevsfromthediscoveryset, ##act, ##y, ##ntcelltypesincrc, peptides d keyresourcestable containing, ##158externalsetsample, ##ification, ##mo, hcby, ##8, rf algorithm, rf mode, ##betweenp, ##feature, ##sing, cellrna sequencing, 2024ll, increasing, ##hing, levelsofaactint, tissues, ##ce, ##cases teins, ##rfdiagnosticmodelforcrcd, luteshrinkageandselectionoperator, fore, ##edthetoprankingpathways, have, ##ultsintermsof, ##als, ##eres, ##ved, ##pr, ##v, ##xa, ##gg, ##mat, ##obeen, ##ee, ##ro, ##ude, ##ha, biomarkers, base, isolated, ##ter, open, highestrankings, areaunder, ##ject, ##optworankingvariable, ##valuable, 202, ##ld, um, ##ach, ##heurineofpatientswithmetastaticlungcancer, final, high, ##iatedpathwaysenrichedinev, sha, ##leastabso - markers, uniformmanifold, mass star + methods, protein lysate, ##4, ##wer, bio, ##les, ##inenriched"
A (10).pdf,"colorectal, stomach, CRC tissue, plasma, colorectal tissue samples, liver, APOA1, Colorectal cancer, Fayazfar S, ORM2, FGB, CRC patients, C4A, polyp, lung, cancers, Plasma, plasma proteins, KRT1, colorectal cancer, breast, FGB and, IGJ, ALB, H, E., cancer cancers, cancer, CRC","crc, -, mor, large scale, world, plasma proteomic analysis, apoa1, ##gb, ##3, 000, hunting, , 000, orm2, advanced, ≥, home, plasma b, e, colorectal cancer, ##oma, c4a, ##faya, 14. 1 million new, university of medical sciences, tehran, iran, alb, ##hos, cancer, poly, 18 july 2019, hepa, tumor, regulated, ##omatou, liver, 1, 12 april 2019, decreasing, by, c, krt1, - 58, fold, plasma proteins, 18, ##can, normal, mortality, ##far, ##hes, cr, 960, ##p, breast, tabulation, regions, stomach, 30, 184, paramedical scie, sex, third, cancers, lung, ##teomics, ap, 000, 72, ##bo, down, g, hpr, 74, ##page, up - regulated, 8, death, graphical visualization, plasma, ##38, aden, ##ci, fgb, igj, 14. 1 million, color, 3, or, ##1, ##0, ##al, 2, ##ect, proteins, ##a, hp, significantly altered, f, change"
A (11).pdf,"patients, breast cancer, tumor, malignant tumors, plasma, basophils, IL7, anticancer, IL10, CXCL12, Cancer, cancers, prostate cancer serum, MCP-3, Z., TCPDF, F, PY-, IL15, colorectal cancer, blood, tumors, neutrophils, Hodi FS, node, cancer, CXCL1, serum, CRC","##sis, ##2356, crc, l, f i, rural, incidence, 0, r, positively correlated, higher, medic, scientific research project, difference, ca, and, new, blood - based, protein biomarkers, 107, proteom, advanced, 0. 9924, u, absolute count of basophils, prostate cancer, serum protein signature model, colorectal cancer, basic research, conflict, 10766, urban, 8992, t, cxcl, o, 185, ##stasis, scientific research, serum and, conflict of interest, cx, ##23, ##56, circulating, ##x, ##era, 17, ##pdf, plasma protein levels, tumor, pan, guangzhou, 1, <, ##e, mcp - 3, ##ea, cxcl1, ang, en, cm, cl, 10755, 10768, c, science and technology program, second, version t, cr, breast, guangzhou medical university, tumors, medical university, m, pro, dovepress, fifth, urban areas, 555, 000, mc, central hospital of guangzhou, 286, 000, ##c, hr, absolute count of neutrophils, cancers, ##ylation, il10, stages, ##66, 2024, university, introduction, mcp, ##cer, ##omics, urgent, non, g, wan, i, low and high throughput, science, fl, invasive, 4 changes, plasma, a, distant, central hospital, inflammation, meta, panyu central hospital of, il15, training, deaths, hospital, ##sta, cases, serum protein signature, dove, technology, ##ce, 4 cm, anti, nunez, j, basic and, prostate, group, 10 december 2024, nee, tc, align, 2, pote, ≥4, proteins, s, basic research foundation, il, system, serum, f"
A (12).pdf,"colorectal, normal tissues, JianvHuang, peripheral, adenoma, CRC patients, tumor, samples, CRCisarapidlyincreasinganddeadlydisease, CRC-, par-, plasma samples, CRC","patients, ##anelof, crc, l, ##met, -, 0, ##de, ##fen, ##gno, ms, 57 ofwhichwerethenstoredat−80◦C. 8of11, ##promising, ##idandlipid - likemolecule, ##metab, 4. 1 study, 2025, ##aceticacidant, ##liquidchroma, ##ide, particular, ##thatcanfacilita, tumor, lore, 26, guangzhou, ##pl, ##day, ##ane, to, ##you, ##ng, ##mark, 112, ##eim, ##2, ##ductedanuntargeted, ##zen, nanjing, million, ##rcearlyde, cr, ##lyde, ##arlyde, jian, ##ficationofmetabolitesthat, colorect, ##ctalcar, ##leunder, ##eobtainedduringsurgeryandsubsequentlyflushed, likel, role, introduction, ##bolomics, ##con, ##oseimplicatedinli, showed, tabolites, all, outstanding, biomark, ##cre, ##do, ##thi, ##bythenationalnatural, nt, trained, ##ico, ##asi, ##fasting, ##8, ##genesis, ##sar, studies, controlstudyinkunming, ##material, ##lip, ##ab, 1. 9, ##gua, sevenmetabolites, ##aladenoma, ##supportings, inc, nc, ##wer, ##dingsprovide, ##separatein, 10, lewangandxiang, we, ##21, ##el, ##nc, ##sic, ##crcandaffordnovel, ms / ms, diagnosed, ##arapidlyin, ##20 %, ##bloodaf, ##to, pi, ##name, metabolomics, ##ries, ##sunaturalscience foundation, ##b, ##ofcolorect, healthcare professionals, ##ptimalperformance, underlying, one, ##cino, ##ciesand, ##open, ##au, 239, ##tec, 109, abstract, ##ra, ##cr, ##whiteblood, ##nga, ##chang, seven, accounting, 6000, ##inatwo - stagecase, ##forfuturecl, ##isan, ##91, metabolic, 0. 9 million d, naturalsciencefoundationofguangdong, ##ma, ##med, ##ac, ##lyto, ##validatet, ##ulant, ##work, ##lp, ##under, ##qually, ##iling, ##cca, case – control, methods, sciencefoundationofchina, provided, ##specialyoungtalentplanofscientificand technologicalinnovation, ##causeof, ##lydetec, peripheral, ##dm, deaths, ##one, ##tc, ##ative, ##ly, nationalscienceandtechnologymajorproject, ##ben, biomarkers, ##ter, gbiomarkers, high, 5 ml, 28. 8 %, ##cplasmamet, et, ##ag, ##lof, ##eter, ##ori, controls, ##change, ##si, ##creativecom, 164, r, ##unt, earlydiagnosis, ##eases, ##fundo, ##use, ##rem, ##colorectal adenoma, ##metabolites, 9, ##fi, ##peci, ##ing, our, ##nov, ##rovidenovel, ##of, ##dong, ##thechangeinme, normal, ##s, ##cancer, redbloodcel, particularly, ##hes, eat, 97, ##hecreative, ##biomark, ##asmametabolomic, ##gur, . 9 million, ##c, ##ful, ##ar, ##for, ##collection, ##nimumof8, ##ance, ##fjiang, yet, ap, ##ers, ##pidlyin, ##uti, ##re, ##bu, metabolicdisturbanceplaysacritical, ##hi, ##inical venous, 219, as, ##asma, ##blood, ##rce, meta, ##ublish, ##ex, ##ara, ##lizedmachine, noncommunicablechronicdis, ##ples, ##ngand, income, ##cp, ##designandpopulation, ##rcversus, bloodsamplesboth, thee, med, ##pe, and, ##ndxia, ##ana, full, ##tha, ##ectedmetab, massspectrometry, plasma samples, par, ##findingsprovidenovel, ##tography, ##nd, allmalign, ##biomarkers, this, promofin, ##eta, ##enediaminetet, ##termsoft, 1, ##xia, ##bol, ##hyl, ##sam, ##9, ##lasma, ##encesinpl, lew, tod, ##ergymetabolisminco, ##by, ##the, evidence, 30. 6 %, stable, distribution, 91, camsinnovationfundfor medicalsciences, ##in, research, colorectaladenoma, less, ##lasmametaboli, ##anfacilitatec, three, ##mostcom, falsedis, ##edbysichuaninternationalmed, prof, duc, ##nti, bloodsamplesweredrawnprior, ##and, 4, ##tudyreveale, sample, ##using, ##fin, study, ##ho, ##ami, ##mic, ##ci, mechanisms, ##gnosticperformanceof, ##etabol, ##have, tissues, color, ##wentrapidcentrifugation, ##promisin, lip, ##hs, ##th"
A (13).pdf,"CW-2, patients, liver, Colorectal cancer, CRC cell lines, w/v, mucinous carcinoma fetal bovine serum, ANGPTL2, amino acid, Colo320, gastric cancer, LoVo, human CRC cell lines, penicillin, Caco-2 cells, gastric cancer cell line, Colo205, NCC-CoC-K115P, angiopoietin-like protein 2, colorectal cancer, Caco-2, FBS, organs, Cells, WiDr, cancer, serum, CRC","##ken, ##goshima university, 1 - 21, ##sis, 100 µg, crc, 1. 2 million, disease, 0. 1 mmol / l, 20 %, meta, co, higher, ca, ang, cw, pen, deaths, fetal bovine, ##sta, angptl2 i, mu, 100 u / ml, ##ma, angiopoie, ##ce, 7, culture, ##cino, col, cr, school, 89, / ml, center ka, >, amino, ##us, ##icillin, ##gnancy, ##l2 colorectal cancer, non, carcino, ##our, nc, angpt, protein, biores, gas, serum, 8, ##c"
A (14).pdf,"patients, colorectal, CEA, Solid Tumors, F, TheWalterandElizaHallInstituteofMedicalResearch,1GRoyalParade, Cancer, tumor, DNA, Tsui, tumor DNA, SciTranslMed2014;6:224ra224, Circulating tumour cells, ctDNA, Tie, Tol, ofcolorectal","treatment, l, dna analysis, ##llow, disease, ##at, which, -, ##gencyclinicalresearchfellowship, tumorcellscirculateintheperipheral, ##694000de, metastatic evaluation criteria, ur, ##ofcirculatingtumordna, mutant dna, and, he, ##chemother, evaluation, ##unt, ##somatictumor, ##by, ie, ##nsitivemet, ##tum, ##cycle 2, ##mas, solid tumors, ##dy, quantification, ##ectalcancer, line, ##yactivetherap, ##gents, the, ##nts, free, with, gold, central, ##tial, ##motherapyandtarget, early, of, ##ge, ##ft, serial, ##herapeuticregimensforpatient, ##untfor694000deathsper, amino, limita, combination, ##dentified, heeuropeansociety, ##cology, ##to, limita - disease, ti, ##withct, ##fi, ##corre - lated, ##che, ##ord, ##analysis, ##bserved, response, cancer, monitormetastaticbreast, circulating, ##ema, ##me, massively parallel sequencing, ##hea, statisticalanalysis, ##dis, tumor, ##al the, nonparametric progression - freeandover, ##eintumorsize, ##pl, detection, ##are, ##asa, victorian, ##e, ##amplesforthisstu, ##yactivetherapies, ##8. 1, ##of, ##t, to, survival, ##mark, ##orsizeusingaseries, ##ct, wethankthevictoriancancer, comparing, ##ysisshouldbeincorporatedintofutureclinicaltrialstoprovide, ##can, ##the, ##urvivalin, candidate, ##s, ##mutationsforctdna, themolecularevolutionof, ##so, ##2015, ##lytothi, please, ##sin, ##jorcarcinomasbut, ce, ##quanti, allsurvivalinadvancedcolorectalcancerpatients, inter, ##metastaticcolor, ##52, ##eria, blood, fluorescentmagneticparticlesfordetectionandenumerationofgeneticvariation, on, tumorigen, ##in, ##chang, ##biomark, pro, ##universitypressonbehal, outcomes, mc, ##ement, sundinaetal. t, ##dna, ##quiredresistan, transforming, 30, ##targetedegfrblockadeincolorectalcancer, hr, ##ulatingtumordnain, published, poor, bothauthor, ##ated, ##biobankforprocessingsome, rst, intraobserver, . 7vers, ##all, ##ted, ctdna, ##ies, ##year, ##rarem, ##se, ##for, ##patientswithmetastaticcolorectalcancer, ##tri, specific, ##ath, ##mutationsandsub, ##ma, duringfirst - linechemotherapypredi, ##oft, ##ac, ##ein, ##statistics, ##fo, ##namolecule, tu, ##eda, ct, ##tumorsize, predict, rep, these, ##cer, ##ub, ##quent, ##and, ##ands, ##as, major, ##with, ##urvival, ##on, lesser reductions, ##bu, ##rityofpat, ##circ, ##asman, ##formedical, descriptive, ##enes, it, ##befor, ##thes, ##lc, ##dforquantitat, responses, ##ad, ##mutationsinmultipleg, meta, imaging, ##sper, significantreductionsin, ever, †, ##oxford, ofini, ##8, ##mo, ##sing, early - andlate - stagehumanmalign, increasing, – 10weeks, ##sse, rapididentificationof, ##static evaluation criteria, ##arerequiredforcan, ##pani, ##eo, ##themann – whitneyu - tes, rec, receiver operating characteristic curves, color, - didatetissuemutationsweredetectableinthecell - freednafromtheplasmaof48ofthese52, ##werei, ##pa, health, ##ben, ##mour cells, improving, ##lth, ##ini, ##i, more correlated, ##posed, increased, annals, amorerobustassessmentofthispromisingbiomark, ##tre, ##led, procnatlacads, ##wer, progressi, bio, biology, ##forma, circulatingtum, nat, ##dict, ##patient"
A (15).pdf,"patients, tumor, plasma, Colorectal cancer, Cancer, cancers, Patients, tumor buds, malignant neoplasm Patients, CRC patients [10], colorectal cancer, Jun SH, Cell, rectum, colon, cfDNA, GS, CEA, tumors, perineural, tissue, mucosa, FP-S, colon cancer, cancer, CRC","neo, cea, ##mata, size, crc, como, ##ection, fold higher, l, disease, ##rb, -, higher, - thirds, mu, cn, within 2, 3 folds higher, e, colorectal cancer, ##idities, manipulation, 185, colon, surgical, 9, resection, ##jo, extracted, ##er, cancer, over, tumor, fragment, tn, 1, increases, cfdna, su, 903, 000 deaths, graphpad, lower, fragments < 400 bp, cf, des, so, fold, 2. 4 - fold increase, 3. 1 - fold increase, 1. 3, cr, ##p, wilcox, % to 50 %, increase, 1. 9 million, tumors, fragmentation, surgical manipulation, 60 years old, ##gnant, th, three, 406890 /, fra, intraoper, ##phovascular invasion, cancers, graphpad prism software, tissue damage, stage, ##pq, resis system, ##tic run, ##as, longer, ##m, friedman test, app, form, greater, electropherogram, surgery, plasma, res, meta, intra, 36, > 5 ng / ml, ##sta, electroph, tumor buds, gments > 400 bp, rec, tapestation equipment, color, significant, 440, 3, test, elevated, electro, ##omic material, 2, high, perineural invasion, increased, nucleic acid isolation kit, automated, ##pho, magmax cell, ##cos, f"
A (16).pdf,"patients, colorectal, tumor, antitumor, lymph node-like, cancer patients, Nebozhyn M, Colorectal cancer, human, human colorectal carcinoma cells, CRC patients, Huang J, Cancer, cell, cancers, Patients, colorectal carcinoma, body, CXCL11, samples, colorectal cancer, Sagi-Assif O, Cancers, colorectal cancer patients, CXCL10, tissue, tissue samples, cancer, Cancer J Clin, peripheral blood, CRC","patients, cxcl11, ##xcl, crc, polymerase chain reaction, ec, higher, - like, ca, cxcl10, human colorectal carcinoma, ##rre, advanced, colorectal cancer, immune gene array, cance, invasion - related properties, 185, cxcl, two, cx, radiation therapy, tissue samples, cancer, ##x, colorectal, tumor, iv, 1, expression, ##e, ##dd, cxcl1, pc, ##top, tt, c, ##oo, higher education, science, indicators, concentration, lymph node, metastasis, and technology, ##w, million, conflicts, cr, unique, therapy, between january and august 202, ##ff, tissue, ##pp, chemotherapy, esti, antitumor, pp, primary colorectal carcinoma, ##cc, rsitas, oncotarget, cancers, stages, stage, ##7, ##edd, differences, ##wee, unive, ##11, universitas, g, referral hospital, bb, ##fin, biomark, ##r, five, metasta, larger, ##y, meta, 54, 6, 36, ##sta, ##cl, ##xcl11, rec, color, ##al cancer, 3, structures, colitis, ##al, ##tok, ##dings, fundamental research, variation, pcr, bio, 11, peripheral blood"
A (17).pdf,"patients, NC, arachidonic acid, allocholic acid, plasma, oleic acid, fatty acid, homocysteine, lipid, CRC cell lines, cially, Figure 1), Fecal, phenol, adenoma, L-histidine, plasma samples, androsterone sulfate, adenoma-carcinoma, food-derived, cholic acid glycine, linoleic acid, CRC","arachidonic acid, crc, ##met, tia, 43, ##let, ##paratedcl, -, at, enriched, we, ##indole, ##calsam, and, ##co, ##ofalteredmetab, ##quence, ##ando, progression, ##idmetabolites, ##inchemotherapyresponders, - ms, pls -, 138, ##ductedmetabolites, chemotherapeuticresp, ##metab, ##abolites, ##nc, advanced, ##thed, ##metabolic, ##yin, with, ##ific, lc, ##metabolitesalongtheade, ##enrich, ##metabolites, 878, ##oma, ##eca, o, ##4sequen - plasma, ##nd, instage, cancer, ##ual, ##reeind, chrom, ##mento, ##tes, melleolide, ##mp, ##bet, ##hea, ##sw, cholic acid, ##ites, ##non, ##hort, ##pl, ##s -, ##3, ##ares, ##are, carcinoma, 1, ##tidine, differential, ##e, ##ea, ##ofpro -, ##rc, alpha, ##very, ##cal, ##om, plasma metabolome, cra, ##pleswerep, weidentified, ##pls -, ##wed, ##of, to, ##fe, pair, ##sintothefunctionalsign, cia, ##erfromothermetab, ##pon, ##so, normal, ##dh, his, legend, ##the, alterationofmicrobialmetabolitesinstagesofcrc, metabolites, alpl, l - histi, ##fc, de, cr, fattyacylestersofhydroxyfattyacids, - apartfromplasma, ##ins, ##pathways, endogenous, ##cr, ##ll, glycine conjugate, ##depletionofdheasulfat, ##pletion, ##ep, ##in, specificpeaksofselecteddifferenti, ##aboli, ##masamples, ##entialpl, ##vid, da, ##di, ##ces, individuals, ##c, lc - ms, ##lm, un, lin, ##olic acid, ##his, ##calandplasma, 37, ##top3differential, ##discovery, comparison, ##ma, different, ##ome, glucose - alaninecy - fecal, ##no, ##ance, top, ##analyses, fa, ##sas, ##dt, ##ignatures, ##int, ##de - litesa, these, ##asmametabolites, ##ers, ##con, ##119patient, homocysteine degradation, ##and, ##as, ##eofmicrobialmetabolites, ##nin, ##11, ara, distributions, sign, heatmapofdiffer, ##ion, heatmapofdifferential, pls, all, ##cal metabolome, ##lmetabolites, ##thattheplasmfindings, ##ole, ##lly, ##fcrc, ##progression alteration, ##asma, ##metabolitesin, ##is, plasma, ##rosterone, adenoma - carcinoma, 22, respond, oleic acid enrichment, meta, micro, ##bial, fatty acid, ##cala, aden, cle, ##ver, ##entialmetabolites, ##off, ##etabol, ##crc, olites, ##6 –, correlationand, ##formedase, ##ography - mass spectrometry, phenol, significant, non - responders, 143, ##id, oleicacidin, liquid, tumorigenic analyses, 1387, altered, ##functionalrol, 29, ##1, ##lth, open, alteration, ##aredton, ##fecalmetabolites, ##ab, ##sulfat, ##crcco, ##gaininsight, ##cco, ##tage, ##chemotherapy, 988, alterationofplasma, 373, ##ets, ##nr, carcinomas, f, ##patient, ##lenicaci"
A (18).pdf,"patients, Tumor, Cancer, human, Altman, KET, WNT5A, Brenner H, HB, colorectalcancer, IntJ, BHM, Chang-Claude J, CRC","##center, ##eneand, dna, ##tingrelativelyst, crc, ##met, ##anda, ##at, ##stic, -, ep, we, ##de, under, and, ##jun, ##ousexternalv, confidence intervals, ##ty, 10522, ailaddress, ##lance, ##ss, methyl, ##their9, sevens, ##rgenumberofprogno, cox regression analyses, ##ectalcancer, ##lystronglevelofevidencefor, ##thenewlyobtained, with, ##ft, e, ##markers, ##onanevidencescoring, based, ##gram, ##siveasse, ##ssociation, ti, ##le forcolorectalcancer, ##io, two, implications, ##analysis, tumor diseases, ##thenewlyobtaine, ##biomarkers, this, ##thylation, ##ersandtwomult, ##evens, ##la, validation, ##mento, relevant, formostotherproposed, ##ing, our, ##bt, w, ##pro, ##lebiomarkersandtwomulti - biomarkers, nc - nd, ##ures, ##aridentified, ##are, ##rel, rt, ##14, ##cdkn2apromotermethylation, ##lege, ##10year, ##ck, ##ting, ##wn, ##igenetic, ##of, ##ste, ad, 1a, cia, ##mark, ##es, ##a - analysisofpreviouslysuggested, ##d, mailad, ##st, ##nsing, ##ri, ##had, ##by, ##can, ##the, ##fromoure, ##studiesinepidemi, ##open, imne, methylation, evidence, ##ltiplegenebiomarkerswer, cr, ##rgenumber, ##1st, ##120, ,, cis, sevensingle, ##mingatdeveloping, ##cr, external validation, reduced, ##ciation, ##alval, ##in, ##29multiplegenemethylationbiomarkers, ##biomark, ##meta - analyses, ##pot, ##ersforsporadiccolorectalcancer, build, ##di, research, ##previousmeta - analyses, ##c, ##venmu, colorect, ##dna, ##ces, ##cd, th, ##foundsevensingle, ##genemethylation, results, hr, published, ##leunder, incorporating, screening, ##rand, ##venmultiplegene, 37, ##ene, conducted, ##se, ##eadingcauses, ##alcancer, ##geneme, biomarkersandtwobiomarkerpanelsforcrctobe, majority, ##leg, ##mise, ##oft, ##feld, ##ance, ##prehen, ##ac, ##fo, 2024, ##ass, ##dt, ##geneous, ##ers, ##cer, het, ##and, subsequent, ##dent, ##re, ##with, ##ified, iso, supporting, ##pt, translationin, ##5 %, ##van, ##idationand, ##edhazard ratios, ##panelsofgenemethylation at, ##24, colorectalcan, ##and methylation, fate, ##genemethylationbiomarkers, colorectalcancer, 0. 9 million, ##siveeva, biomark, as, ##potentialclinic, ##ation, ##lc, e - m, did, meta, consultation, im, deaths, ##sing, interpretation, have, ##gor, guidelines, march, ac, alargenumberof, ##online, ##ly, ala, 2303, ##gnostic, ##ex, ass, wei, biomarkers, ##1, ##151, ##pool, ##dates, between, 202, ##methyl - studies, forcolorectalcancer, ductedacomprehensive, ##i, ##rong, ##urfindingsbyprioritizing, ##atures, 0. 9 million deaths, ##ccby - nc - nd license, analysis, ##twobiomarkerpanelsforcrct, ##tern, ##4, ##cp, ##20, weidentifiedcandidates with, ##eve, ##patient, ##videdacom"
A (19).pdf,"patients, tumor, TheisolatedEVswerechar-, plasma, ColonTrack, tissue EV samples, W.G., patient, B, TheColonTrackmodelcouldbecome, Extracellular vesicles, biomolecules, S1P, PERM-, C.-Z.G., rele-, cancer cell, carcinoembryonic antigen, NTA, EVs, CRC screening.6, CEA, blood, tissue, p<0.001),adifferencemorepronouncedthanin, plasma EVs, lipids, serum, CRC","cea, size, nanopar - proteins, ##sub, acterized, 517 quan, crc, ##met, tis, ##c diagn, ##sho, ##swere, ev, ##unced, ##he, dia, ##gno, pro - significantlydy, ##proteome mulationandenrich, – 20 ev - encapsulated, adi, ##provid, energy meta, - exclusionchrom, 5, 496 proteins, ##filingoft, derived, - ms, spannedfiveord, ##dy, ##didatecr, ##sofcrc, ##seinclu, ##metab, weexamined, ##mu, the, evproteomics licates, ##kit, limitationsoft, ##tha, ##omp, ##gre, al analysis, ##markers, ##dulate, ##fied, quantitative proteomic profiles, ##not, ##oth, seen, affected, te, ##pha, ##fle, ##ssug, car, ##atography, ##inducedb, inmostpl, ##broaderdiversity, evproteomesofpatients, ##edint, ##ant, this, ev - derived proteins, ##cellular, diagnostic model, ##tably, ##withcrcan, 17, multi, ##bet, tumor, ##pro, ##tein, ##pl, ##ult, ##ssion, ##maybed, ##delands, dysregulated proteins, may, ##ea, ##used, ##ofcrcc, ##fr, ##chofthecurrentresear, ##very, ##gul, quantitative, en, ##lity, ##ctionbet, ##top, evmarkersinourdataset, - staged, ##non - coding rnawithinevs, ticle tracking analysis, ##ntifiedinthisst, so, ##ct, ##by, 18, ##the, ##so, ##rossallrep, ##ofma, wgcna, ##au, ##ip, me04 —, cr, evproteome, ##crcp, ##481up, transporting, ro, arelesslikelytobedegradedandthereforearemorereliable, ##ins, ##thepl, ##ythetumors, ##bytransmissionelectronmicroscopy, ##las, ##nse, ##directly, ##organs, 2, 088protein, ##dhc, collectedthrough, ##quently, ve, ##jects, tissue, ##in, ##fully, comprehensive, ##ign, protein, ##don, bloodstream, ##maymo, pcoa, 25, other, published, plasma - derived, ##ev, density gradient centrifugation, ##nt, ##aturepro - star + methods, ##ye, diverse, discoveryofcan, ##theres, ##for, cell, ##cinoembryonic antigen, 195, ##ma, ##bleintensity, they, ##cha, ##int, these, ##tudy, ##ccu, ##has, ##and, ##isolated, ##through, ##furt, ##vealedacleardist, ##as, ##re, ##wee, ##capsulate, ##teinbiomark, ##nin, ##bio, ll, carry, ##onlineversion, ##par, ##com, ##xhi, ##ch, detailed, all, it, ##asma, figures, ##her, invasive, ##udy, ##thes, plasma, ##ho, ##while, ##acces, nt, me, ##ere, ##mo, im, tissueev, 40, 21whiletumortissue - derivedev, ##dsare, ##cl, – 14circulatingev, ##orbee, tissue using, ##60, ##u, ##abolic, re, liquid, ##bution, robust, ##ofevsareheterogeneous, biomarkers, ##sicles, open, 2, ##universal, ##than, serum biomarker, forplasmaevs, proteins, high, ##themssignalintensityofbothconventional, ##ofthispaper, ##cteristic, ude, ##psy, ##focused, ##tails, analysis, bio, d, ##defort, ##patient"
A (2).pdf,"patients, CRC tissue, tumor, SERPINF1, plasma, cer, CRC patient, patient, C5a, Colorectal cancer, anaphylatoxin C5a, CRC patients, LRG1, Figure 6C, cholesterol, Plasma, SAA4, neural network, lipopolysaccharide-binding protein, SERPIN, sera, assays.4, C4B, Complement protein C5, colorectal cancer, sup-, immunoglobulin, ceruloplasmin, apolipoprotein C2, SERPINC1, node, C8A, cancer, serum amyloid A4, cancer-, CRC","crc, l, ##gn, complement c5, lbp, gdansk, dia, protein signature, ##oxin, complement proteins, ms, faculty of biotechnology, alpha - 2 - glycoprotein 1, open access pages, 4. 0, ##ei, of gdansk, abrahama 58, ##5a, ##l, advanced, the, plasma proteomics analysis, c4, center, of, lc, commons attribution 4. 0 license, ##cology, - transformed, sage and, 5 year, c5a, ##cy, university of gdansk,, c4b, adeno -, survival rate, cancer, validation, c5, tumor, w, secret, mali, 1, ##ecta, pathologists, may, institute, levels, gamma 2, c, ##tive, ##ra - biomarkers, amyloid, intercollegiate faculty of, - early stages, heavy constant, l cancer, ##munoglobulin, vali, 5 can -, metastasis, cr, ##p, quan, ##lat, cancer stages, on, low, elisa, 13, pro, protein, members, lipopolysaccharide - binding protein, ##c, an, mass, un, ser, antibody - based assays, ##his, 00769, peptide, proteomics analysis, enhanced, complement cascade, in, ##sti -, stages, aftecc, tu, ap, cal, serpin, ##qlr, proteomics characterization, university, protein chan, 4, enh, con, ##uti, linear model, sa, university of, down, sample, app, 325, ##ker plots, i, science, incident, ana, ##te, neural network classification, na, biomark, c8a, plasma, ##cu, ##vas, inflammation, men, 37 were changed, im, pages, 25 %, pe, degradation, serum, cu, anti, rec, develop - gen, color, prom, cat, ##v, ##phy, complement, altered, ge, ##pin, 202, proteins, ate, january, increased, abrahama 58 street, healthy, can - cer progression, ##a, matous polyps, % to, bio, intercollegiate, lower than 10 %, si, apolipoprotein c2 (, c1"
A (20).pdf,"patients, Neovascular Age-Related Macular Degenera-, Cancer J Clin 2021;71(03, Its, Shimura T, Colorectal cancer, Cancer, CebriánA, Material, Patients, beta-2-microglobulin, ProteinTargets, B2M beta-2-microglobulin, colorectal adenocarcinomas, JColoproctol Vol.43 No.3/2023, samples, colorectal cancer, urinary markersinColonAdenocarcinoma, Colorectal, YueF, Cancers, CEA, Colorectal Cancer, CRC colorectalcancer, TheLC, CRC","##identi, ##col, ##olo, ##doncolono, ##ection, 10, ##from, ##tainde - globocanestimatesofincidenceandmortality, 149014, ##de, we, ur, ##gno, jc, and, ca, ##bra, jon, university hospital, ##val, survivalrate, ##hat, ##ate, 216, protein biomarkers, ##functiongeneontologytermann, talcancer, ##dy, there, ##colorec -, valid, ##dia, ##xi, early localized disease, ##idatethesebiomarkercandidatesinalarger, advanced, proteomics, ##vival, the, with, markers, ##ves, ##potential, of, colorectal cancer, different analysis approaches, tenproteins, ##base, oachestoindependentlyverifyandval, 185, ##ind, ##chemist, current, ##ithout, wethanktheteamofresearchers, ##trometry, ##thesebiomarkercandidatesinalarger, ##to, sis, ti, ##fi, surgical be, car, ##wereidentified, ##20. 1, ##analysis, ##al conflicts, crucial, ##isa, this, cancer, ##ur, ##eta, ##authorsdeclarenoconflictso, year, ) - biology, ##in chim act, colorectal, ##dis, regulated, ##teomic, mali, w, ##uri, ##atlythankandack, ##pro, ##tein, ##are, ##asa, 2020, ##crcin, personalized medicine, ##gul, ma, ##cancerstatistics, urinary, neovascular age - related, ##5, ##of, advances, cl, to, gene, ##fromnonpatholog - thisstudy, ##oli, survival, up, ##es, ##ode, ##st, ua, —, int, ##14 %, new cases, bea, finterestrelatedtothis, ##ct, ##the, ##2, massspectromet, lbqp, b, ##cancer, ##forear, 178, cr, ce, cancer group, referred, ##commendthatcrcscreeningshould, ##shi, successfulapplicationincancer, ##ry, ##lowero, ##da, ##ith, 470, 1. 9 million, ##withdiffer - te, ##ep, march2018, ##in, ##aths, macular degenera - tion, ##ue, protein, ##pp, ##tist, identification, ##sassociated, ##c, brasil, ##patientswithcolorectalcan, mass, average, ##pre, 49year, molecular, ##denocarcinoma, us, ##fy, expertrevproteomics, screening, om, ##icalsignificancewithap, ##useofcancer - relatedde, ##theproteomicprofile, ##975. 000, ##static, ##ob, ##ath, cancers, 62, beta - 2 - microglobulin, ch, (, ##ease, subsequentstudiesareneededtoevaluate, ##andthesecondleading, ##andalm, global, ##hassomelim, icalindividualsversus, ##ear, aiming, ##markerprotein, ##itation, ##and, subsequent, ##forth, la, ##as, ##re, ##with, ##patientsthroughdifferentanalysis, ##omics, 14, app, ##tional experiment, department of colorectal, whichisbothdiagnostic, prote, 1396893, ##erfor theearlydetecticonclusion, all, biomark, ##levanceofmass spectrometry analysis, ##90 %. 2, surgery, ##r, ##gh, 21660, ##guide, risk, al, ##proteinsarep, moreshorterrunsforanalyticalmethods, ##sco, ##vic, res, 2015, ##tothereal - life, micro, ##diminishedexpressionofapodisrelatedtolymp, ##ltblood, ##op, ##eval -, ##thelab, ##ver, ##betwee, nancy, 692272, ##ofurinesamples, ##esareneeded, ##sta, ►, 36, ##cl, strategies, ten, ##vers, ##lines, recent, color, faecaloc, ##ly, ##narymark, colorectal adenocarcinomas, ##ca, or, ##lydetectionof, ##npatientsintheexperimental, 2, ##ona, ##i, 45, references, ##led, ##ocarcino - colorectal cancer, ofthecolorectalsurgeryde, mass spectrometry, ##brasileirade, ##tu, proteintarget, martins, colonoscopy, low number, biochemistry and protein chemistry"
A (21).pdf,"patients, GDF15, [7, 9]), rectal cancer, HPT, SPON2, NPV, human hepatocytes, PRDX1, Endoscopy II, cirrhotic liver, C-reactive protein, Osteopontin, colorectal cancer, Ferritin light chain, propor- Endo II CRC, H. H, Serum amyloid, Stachelski, blood plasma proteins, cardiovascular, cancer, ECH1, trefoil factor 3, TFF3, MIF, Human, Colorectal cancer, Tumor, PQC, Eser S, CO9, Selenium-binding protein, PSGL, Glycine-, Tissue metalloproteinase inhibitor 1, Nielsen BS, Haptoglobin, TIMP1, KC, PKM2, CEA, Dipeptidyl peptidase IV, SAA, ulcerative colitis, F., FRIL, Peroxiredoxin-1, [10], colorectal neoplasias, macrophage, Kai K, mitochondrial, DPPIV, alpha 1-acid glycoprotein, lung, Food, glycoprotein ligand 1, Blood, Tanaka T, Colorectal neoplasms, samples, Spondin-2, Endoscopy II samples, Trefoil factor 3, Macrophage, RB, Int J Mol, Transferrin receptor protein, column, CRC, Gelsolin, K, P-selectin, Cancer, A1AG, L., Int J Cancer, dienoyl-CoA isomerase, C-reactive, SBP1, TFRC, Pyruvate kinase isozyme M2, CRC signal, Wheelhouse NM, Crohn’s, serum amyloid A, Prolyl endopeptidase FAP","31, improved, ##minate, arthritis, crc, serological biomarkers, per, differentiate, diego, ca, ppv, rectal cancer, ptidase, ##ym, rate, usa, 957 564 72 240 34 study, ##uvate kinase, np, . 2 %, late stage colorectal, properties, 12, twenty - seven, laboratory automation framework, full, χ, 7 april, markers, literature, early, colorectal cancer, sep, acute phase proteins, 32 299, ##oma, negative, based, blood plasma proteins, p, targeted - mass spec - 37, rb, macrophage migratory inhibitor, gel, crc - related proteins, assay, cancer, this, validation, 171 13 81 9, 28, inflammatory markers, 14 july 2017, trefoil factor 3, 150,, 26, 18 65 12 selected, npv, 1, 405, ha, 150, san diego, ca, 605 340, eight proteins, 34 300 190, ul, mi, ##fr, coli, c, . 5, au, r - endo ii, ##d, crc test, amyloid, int, one, positive, ic, factor, de, cr, improve, transfer, selenium - binding protein, 700, 000 deaths, growth, macropha, low, li, . 1, diagnostic groups, 2017, fi, ind, 0. 80 / 0., ##c, tim, 135, snk, 21, screenifind, pp, large sample set mir, screening, 92121, 4435, colorectal neoplasias, 36 858 510 48 248 17 for, lung, ##lo, classifier analyses, in, ##al method, ##oh, endoscopy ii, acute - phase p, ##mptomatic, page, reactive, prolyl endopeptidase, sp, 92, ##on, sa, ##pt, expanded, g, endoscopy, 35, 71, tr, nt system, primary, as, tissue metalloproteinase inhibitor, ##brino - transl, compleme, ##sol, 4., ##teom, ##y, ##bution 4. 0, four, 4 million, 713, os, pe, cases, crc signal, increasing, lethal, alpha 1 - acid, sensitivity / speci - fi, sb, ak, 1189, proximity ex, 187, color, analytic, 3, machine learning framework, test, 33 966 579, colonoscopy compliance, improves, itt, robust, concentration measures, biomarkers, 249, ##1, 53, ##mpt, 147, ##cerative colitis, 31 %, high, proximity extension, si, sy, 4698 2759 340, combined, hp, 65 171, dis - tive, rotein production, ##bocan, logistic regression, serum, colonoscopy, rd, restrictive"
A (22).pdf,"patients, IGHG4 Immunoglobulin, GPX3 Glutathione peroxidase 3, FGF-21 Fibroblast growth factor 21, membranes, CA72-4 Cancer antigen 72, ProteomeXchange
, plasma, CRC patients [19], liver, CRP C-reactive protein, non-metastatic, Colorectal cancer, serum AGP1, alpha-1-acid glycoprotein 1, cancers [1, peripheral tissues, AGP1, CRC patients, alpha-1-antitrypsin, specimens, tric cancer, cell, plasma A1AT, cancers, plasma AGP1, membrane, serum, LRG Leucine-rich alpha-2-glycoprotein-1 1Laboratory, CRC [, CFD Complement factor D, CRC Colorectal cancer, C1qC Complement C1q subcomponent subunit C, Heat shock protein 90 kDa, FN, A1AT, pores, plasma proteins, serum/, CEA Carcinoembryonic antigen, COMP Cartilage oligomeric matrix protein, malignancies, C4-A, C4B, beta member)
, Plasma samples, fibronectin, colorectal cancer, Haptoglobin, ine, HSP90B1 Endoplasmin, pancreatic ductal, CA19-9, carcinoembryonic antigen, CRC teins, laryngeal cancer, CEA, HBB Hemoglobin subunit beta, high-molecular-weight glycoprotein, blood, biopsy tissues, LRG, evi- larynegeal cancer, Cystatin C, C4A Complement, cancer, malignant cells, bowel, carbohydrate antigen 19 − 9, C9, esophageal cancer [21], CRC","##sis, cea, ##lutat, crc, l, diabetes, ca19 - 9, lrg, disease, ##bohy, bin, -, 0, heavy, combinations, mor, ##bohydrate antigen 19 − 9, dia, fn, ca, ms, can - cat, nm - crc, leucine - rich, less proteins, ##ol university, crc teins, el elute declaration, consortium, can, can - cate, chulabhorn, proteomics, beta, free, ##drate antigen 19, ##geal, lc, den, colorectal cancer, c9, ##ate proteins, weight, c4a, ms / ms, plasma samples, c1q, - common blood - based, p, car, ti, two, c4b, cancer, circulating, ##bidity, best, ##embryonic antigen, tandem, ##marker, found, bowel, complement c4 - b, f, - 4, regulated, pan, mali, 90 k, lc -, lycoprotein - 1, 1, liver, peptide selections, fdr, ha, eight proteins, h, 2020, peptides, immunoaffinity, complement membrane, dis, quantitative, ##ocarc, gpx3 g, mars, lit, am, a1, c, ##mark, up, morta, constant, pores, plasma proteins, ##cino, biomarker, second, mortality, ##ence, single, inflammatory, a1at, alpha - 1 - antitrypsin, cr, ce, hemoglobin subunit, cst3, ##rg, biopsy speci, 14 background interpretation, ##g - be, plasma level, five proteins, guished, blood, label, low, m, ##chang, es, soluble, raw, protein, identification, fi, gas, agp, spectrometry ighg4, colonoscopy, three proteins, ##bronectin (, an, commons, mass, less, − 4 acquisition, cfd complement factor d, candidate proteins, ##ity, wai, third, - 2 - glyco, liquid chromatography, ar, ##hione peroxidase, metastatic groups, ##static, peripheral tissues, ed, ##cinoembryonic antigen, cancers, ch, ##xd040999 (, attack complex, chromatography, up -, ##romatography, high - abundance proteins, immunoglobulin, la, diag -, ##m, alpha - 1 - acid glycoprotein 1, ##omics, ##on, down, g, non, hc, 14, endoplasmin, biopsy tissues, fn ), publicati, mars - 14, agp1, crp, up - regulated, ##teome, elisa enzyme - linked immunosorbent, biomark, ##cre, ag, invasive, hsp90b1, sappasitthiprasong hospital, ##r, - common, ##lc, ##o, costly, plasma, methods, did, through, nos, distant, res, meta, mac, mars -, ##ay, heat shock protein, ##op, low -, plasma proteome, im, ##ptoglobin, ##sta, colonosco, ##bb, ##ryngeal, increasing, tissues, tion, cu, immune response, re, complement, elevated, liquid, altered, down - regulated, fgf - 21 fibroblast growth factor 21, biomarkers, alpha -, decreased, serum / we, c1q subcomponent subunit c, 2, comp cartilage oligomeric matrix, proteins, high, healthy, increased, complement component c9, acute, ##psy, performance, complement c4 - a, hp, combined, faculty of medicine, ##tham, cystatin c, regulation, bio, malignant cells, ft, serum, c - reactive protein, ##munoblot - blood, flow"
A (23).pdf,"JCYJ20200109140814408, plasma, Holdt LM, human patients, carcinoma, Colorectal cancer, human, stage II/III Colon Cancer, CRC patients, Plasma, line, JCYJ20210324120210029, colorectal adenoma, F, FOLFOX, S100A4, publi, colorectal cancer, FOLFOX-resistant patients, Cell, Rasmussen DN, Wan, CTCs, Shin DH, FABP5, PRM, cancer, BMC Cancer, LGALS1, Bareche Y, CRC","lent cancer type, crc, 831, l, at, 0, waiver, ms, ##gal, ##ry - based, colorectal adenoma, proteomics, u, ##olf, ##markers, ##6, ms - based, colon, data, 126, domain, panel, proteomic, carcinoma, ##teome coverage, machine, plasma peptidome, fu, au, changes, alterations, cr, creative comm, spectrometry - based, ru, shenzhen, on, ##in, pro, clinical proteomics, chemotherapy, ##c, mass spectrometry proteomics, mass, rticle, un, molecular, international lic, china, proteomic biomark - allfinding, wai, 21 : 27, ##olfox, machine learning, page 2 of 13, ##teomics, pepita, fa, is, stage, prm, ##cover - ing, targeted, - independent acquisition ( dia ) method, ##omics, non, prote, ##etry - based, ##te, protein groups, ##iling, mass spectromet, orbitrap exploris, ##if, ##r, 0. 908 wi, plasma, ##bution 4. 0, even, com, ##ver, 240, data - independent acquisition ( dia ) method, ##ox, color, ##al cancer, deep, biomarkers, 53, : 27 page 2 of 13, s, depleted, bio, d, folfox, ##ru, f"
A (24).pdf,"patients, Fu Q, tumor cells, gastric cancer, human digestive, BMP1, GNAI1, LCK, metastatic colorectal cancer, colorectal cancer, plasma samples, lung cancer, non-small cell lung cancer, SFTPA2, non-small cell lung, Que Z, Lu X, exosome cargo, cancer, CB, GLIPR2, teins, surface, tumor, Kang [2], liver, cer, Colorectal cancer, blood samples, mCRC patients, CRC patients, YK2022-7, centri-, RAP1B, RAB35, heart, breast, exosomal, blood, tumors, malignant tumors, early-stage breast cancer, Plasma exosomes, Exosomal TRIM3, RAB30, PSMB8, plasma exosome, cancers, serum exosomes, SMAD3, Xia D, liver cancer, CES1, exosome, CD81, Clin Lab Anal, exosomes, PSMB4, plasma exosomes, CRC, UGGT1, early-stage CRC, ITGA4, plasma, MFAP4, Cancer, Liu X, HMGN5, malignant tumor, intestinal, plasma-derived exosomes, extracellular vesicles, kidney, CD63, H, mCRC, stage III, Fu H, Metastatic colorectal cancer, Tumor-derived exosomal","patients, ra, 5 - year, crc, 10, ##ien, tia, ##ectal cancer, disease, enriched, -, 14 %, 8 – 10 ml, derived, commons attribution - noncommercial - noderivatives 4. 0, ter - proteomics, vary, can, network, u, free, early, lc, colorectal cancer, fast, ##ly expressed proteins, plasma samples, itga, ##stasis, *, adju, te, ti, 320d, cancer, ##cellular, year, colorectal, tumor, mali, rise, liver, gr, ##rc, lb, 965, 963, ##gul, junggar road, 2 karamay, ##mes, 83464985, up, ##7, 100 new, clinical pro, ph, ##ysfunc - cance exosomal proteome, ##omic profiling, ied, ##oso, localized, b, cr, ce, breast, ##kan, small cell, ##ins, 83, radiotherapy, - teins, blood, therapy, ##osomal proteins, label, di, pro, fi, gas, ##ry hospital, sion criteria, mc, ##c, uri -, ##gres - f, sm, psmb, ps, dif - ferential expression, china, potent, ##static, ##mot, , 100 new, 5, lung, ##teomics, treated, different stages, incomplete, stage, 2023, mir, drawn, urumqi 8300, 72, ##on, ##omics, ling, non, exosomes, ##vant, disease - speci, 90 %, prote, 994 quantifiable proteins, biopsy, exodeps, cd, plasma ex, it, rap, karamay, surgery, hm, ag, five, er, ex, plasma, ##phorylated, ##ad, distant, ##imogou district, pat, meta, stage iv, isolation, deaths, nary exosomes, zhu, ##sta, gnai, derived exosomes, march, che, ##vo, color, ##um ex, radio, liquid, shu, open, ##al, kidney, 202, large amounts, differential proteins, - karamay, high, 51, ##gres - fied, monitoring, s, exconclusions, north, 968 pro, western blot, highest, d, ##20, haipeng, 287"
A (25).pdf,"patients, Liu Y, NC, microvesicles, Lata, DON, globular particles, CEACAM, v/v/v)], CD66a, W. Extracellular vesicles, urine samples, colorectal adenoma, exosome-like vesicles, human pancreatic cancer cells, colorectal cancer, urinary exosomes, CEACAM7, human cells, C18, CM
, B [ACN-H2O-FA, cancer, tumor, adenocarcinoma, ±, human, CRC patients, formic acid, F, urinary EVs, Oku Y, pos-, ovarian cancer, cor-, Wu MT, Fusarium graminearum, tumors, GH, Lu SC, Cell Commun Signal, Urinary Cellular Molecular, CEAMCAM6, membrane, CEACAM1, Kil YV, Y. Chmp1A, renal cell carcinoma, Hotta T, Fuchs HE, unfixed, CRC [19], EVs, rat, exosomes, Z. Exosomes, Fu WQ, mouse urine samples, Cancer Lett, Feng W, Thaysen-Andersen M, FA, TA, CRC, TEM, non-tumorigenic tissues, CChhoooossee BBMMCC aanndd bbeenneeffiitt, ESCRT-III, ESCRT, urine, K, human urine, CEACAMs, PepMap C18, CHMPs, Cancer, Exosomes, CM, water, joint, long cytoplasmic, Park M. Chmp 1A, CEACAM5, Hornicek FJ, Varfolomeeva EY, serum","##see, stu - ×, crc, tumor suppressor gene, ##ectal cancer, cy, -, density gradient, ev, tration, convenient, ss, microvesicles, ceacam5, ms, aa, 15 min, ##miitt, 18 january 2023, separated, all - trans retinoic acid, ##itt, cc, ##tro, rrees, escrt, ##aa, ##acam, colorectal adenoma, declaration, fe, u, the, mixture, full, super, lc, pepma, ±ma, ##h, acid, easy - nlc, chmp, ± ±, μ, p, [, ##nary, centrifuging, 9, value, ti, pub - lished maps, dissolved, ##var, free liquid, cytoplasmic domain, cancer, ##cellular, tandem, 78, tumor, pan, human disease, adenocarcinoma, tn, 1, vi, ##rran, significantly, su, h, peptides, ##dd, ##om, human, cm, ##t, tt, ##oo, ##mark, differences between, ph, int, ##2, pl, changes, ##s, signature, helsinki, ##yoouur, em, cr, ce, kind, ##inary, ##crt, dent ’, ##ddy, 60 ~ 80 nm, with column, mass results spectrometry, between 2 1 09 ~ 1 1 011 particles / ml × × ×, ##bular par, tumors, ~ 100 nm, on, ceaca, es, y, pro, protein, mobile phase, ##bm, comparable, rr, individuals, ##acams, ##c, data dependent acquisition group, evs, ceacam7, peptide, ##cc, < 0. 05, ##ms, abe, ##aceutica sin, pepmap, invasion, ##lo, representative te, membrane, ch, ##teomics, ##cles, bbmm, 14, 000 g. 100 μl, ##mic domain, in, renal cell carcinoma, fa, ri, ##romatography, mass spectrometer, samples, ##ub, ceamcam6, con, rat, func, ##m, g, ##ffi, ##een, non, exosomes, ated, ##ch, ##inary cellular molecular diagnostics, science, bb, form, ##ic, soci -, cd66a, 180, migration, ##lence, ##aca, ##r, ##o -, c group, ##rro, analytical column, er, ##nee, ##hh, a, urine, ##y, ##ad, ##aarrc, ##osomes, meta, groups, men, aden, exosome - like vesicles, ##oooossee, ##n, serum, tissues, natl, ac, ##u, diameter, color, ##v, – ms / ms, pressed, ##igen, proteomic analysis, biochem, ##ee, ?, ##nn, 22 november 202, ##mps, biomarkers, ##m1, ##al, urinary ex, ##pad prism 5, tem, ceacam1, exoso, proteins, urina, healthy, increased, 1200 / orbitrap fusion lumos, tumor mark, chmps, ##fcm, nc, po, ff, 50 %, ##les, si, c1, pu"
A (26).pdf,"5-oxoprolinase, pyroglutamic acid, urine, valine, phan, hydroxytigecycline, Colorectal cancer, 9,12,13-TriHOME, Cancer, glutamine, Bas-enhetens ALF, line, colorectal carcinogen-, otic, L-glutamic acid, colorectal cancer, cloxacillin, sup-, unit/ provs amlin, L-tryptophan, Body mass, tetracycline, CL, blood, tumor tissue, NSAIDs N onsteroidal, par-, 3-hydroxybutyric acid, glutathione, sebacic acid, CRC","ram, derivative, oxoode, time, crc, l, ##ectal cancer, at, reversed, ##r -, higher, ##ood, uv, ##ty, antibiotic, nsaids n, metabolic features, 12, body, flu, ci, ##home, e, early, ##xytigecycline, negative, o, ##ba, p, [, pi, 9, two, background methods, ##er, cancer, ##cline, ant, wt wild type, sirius +, tumor, ave, 1, cl, ##ic acid, ##bution 4. 0 international, metab - didate, ##st, ph, tri, statutory r, sebacic acid, , 12, mv, pro - one, onsteroidal anti - inflammatory drugs, cr, 3 - hydroxybutyric acid, six, insights, ,, commons attribution 4. 0 international, hydroxy, se, rib, 5 - oxoprolinase, ##ptophan, 13, pro, seven, umea university, availability, multivar, ##c, ##pto, th, val, mass, un, ns, try, wai, ##biotic, ##ution, ##al carcinogen - didates, 37, page 2 of 13, symptoms, monica - an, vip, ##ome, :, ##yr, in, ##ac, 297, ##yroglutamic acid, ##tracy, ##bolite, ox, ##bolomic biomarker candidates, ##cic acid, candidates, micro - rt, ##bu, g, phase, hydro, 9. 7 years prior, metabolic biomarkers, glutathione, ##tam, ##r, death, 11 : 17 page 2 of 13, balanced, image, valine, meta, ##oglutam, 13 -, ##ver, deaths, 36, early detection, ##ox, anti, l - try, color, 3, rror rate, reproduction, ibi -, l - glutamic acid, open, exact, ##ivar, unit, be, um, cv, et, codes, variation, pro -, ##4, bio, ##lu, error rate, 11, ##ess"
A (27).pdf,"patients, DNA, adenoma–carcinoma, UK, cell-freeDNA(cfDNA)releasedintothecirculationbyallothercells, Thorlacius-UssingO, colorectal cancer, Stage IV disease [1, tumour cells, TanQ, precursor lesions, Nutritionalfactorsandgenderinfluenceage-relatedDNAmethylationin, PHM, TothR, ofcolorectal, Am J Epidemiol, CRC","stage iv disease, crc, ##met, ##sho, ##released, -, ##finding, discomfort, ##promising, cell - freed, ##l, sporadic, ##in the, ##influenceage, for, ##ge, ##color, ##now, were, ##greaterthan, year, ##bisulfite, ##mallp, h, ts, c, unsel, ##mark, npt, ph, ##ct, ##2, ##latedctdnamarkersofcrcispo, methylation, cr, ##nel, ##rnalofcance, blood, ##86 %, ##dna, permission, ##emains, ##claim, ##ts, ##arbei, ##icalrecord, ##pid, is, related, ##con, ##variatesin, ifctdna, ctc, slc8, 868, ##o2, spreaddisease, ##alanalysesan, ##thep, ##ofcell, 83. 8 / 100. 000 ne, ##sing, 25 %, ##n, ##eo, ##isthes, ##hylation, ##os, freed, ##a, ##mour, ##upt, ##ed, treatment, ##col, if, ##co, ##lemarkerswerebmp, ##romoterincolorectalcancer, methyl, ##90 %, ##oma, ikzf, ##to, ##bisulfite - treatmentpro, rc, sfrp, precursor, ##hea, ##pro, smoking, ##crcspecificitywas, ##vi, competing, ##au, ##dnamet, inan independent, ##cr, ##a1, options, ##linicaldiagnosis, f blood, ##stagerema, mad, ##ersofcrcispossibleupto2, ##atedctdnamarkersofcrcispo, laboratory analyses, ##donarapid, nutritionalfactors, ##ated, ctdna, ##year, ##nor, ##methylation, cell, ##din, ##ma, ##med, ct, xu, ##7, ##cer, ##cin, ##with, series o, na, ##andgenderinfluenceage, ##neo, ##o, ##thes, risk, ##jou, 83. 8 / 100. 000, ##hy, ##yearspriortotheclinicaldiagnosis, ##lborg, ##methyl, biomarkers, ##per, ##ctalm, ##itivity, high, ##known, ##spriortoth, 50 %, circulation, ##gerema, disease, incidence, ##si, ##he, ##way, ##local, he, ##cinoma, 86, ##15 %, the, ea, unpleasant, ##inan, ##ssibleupt, ##humanre, regio, based, themostspecific, ##colorectal options, ##ing, ##reproduced, informationfinding, ##me, colorectal, ##dinthestatisticalanalysesand, ##ectedpopulationres, ##rel, ##allothercells, ##of, ##dnabase, lesions, mort, aging, above 10 %, ##cancer, population, earlie, ##ith, reduced, ##ps, ##don, from, ##na, ##l of, ##cinnor, ##c, ##ina, ethics, ##sea, ##lportionofdnareleased, screening, ##humanrectalm, greaterthan, ##for, ##oft, ##was, britishjournalofcancer, tu, british, ##tolab, regional, ##personnel, ##re, ##alcan, g, ##com, reprint, ##vered, released, ##ation, invasive, circulatingtumourdna, ##restudy, stage iv, ##sta, ##hylatedctdna, ##pate, liquid, ##othecirculation, ##hesis, ##ara, ##crcs, ##led, highest, dna, thisstudysupportst, ##ationoftheapc1, fli, ##43 %, ##utralwithregard, ##hypot, ##ft, ##tha, colorectal cancer, ##base, ##uc, this, validation, ##an, ##andgen, adjusting, costs, ##sw, detection, ##cal, ##very, ##hyl, cf, ##sam, ##oma –, ##st, ##ison, ##withhypermet, detectionofk, ##cide, ##by, ##can, ##the, 2021, reviewed, freemethylated, thy, ##fthemostcommonmalignancies, ##ssible, ##for8 %, spread, competingint, ##in, ##nce, ##ist, ##pot, ##biopsy, ##se, 5, ##lo, less invasive disease, ##world, ##othe, appr, yu, ##int, ##and, 4, ##m, ##ofdna, ##ap, ##person, ##wayison, ##cel, 22, aden, ##pet, color, ##eres, universityofaalborgcovered, ##mal, ##stageidisea, ##pc1apromoterincolorectalcancer, over a decade, ##set, ##patient"
A (28).pdf,"colorectal, DepartmentofMedicine, LDL, lipid, UK, Cancer, Received:14August2024Revised:4March2025Accepted:21March2025, TN, Shu1, Theimagesorotherthirdparty, colorectalcanceFUNDING, Zheng 1, ketone, epide-, FAs, followedbytwo-sample, thepotential, colorectum [, low-density lipoprotein, ShuaiXu 1, colorectalcancer(CRC)isthethirdmostcommoncancer, cancer, lipids, triglycerides, CRC","##f78,, vanderbiltep, ##lofcancer, crc, pt, disease, ep, -, ##biobankparticipantsofeuropeanancestrytoidentify, we, per, ##images, ##95 % confidence intervals, ##de, ##he, ##ystatistic, metabolism, if, competinginteres, dysre, and, variants, european ancestry, ##co, syndrome, residual, ##ty, ##25, ##tion, odds, youwillneedtoob, ( mr ), genetic instru, followedbytwo -, competinginterests, lipid confoundingandreversecausation, the, ke, ci, ##metabolic, ##sum, during, ##tha, ##delianrandomization ( mr, ##gly, ##ology, ##delian randomisation analyses, acid, uk, ##ind, 2025, ##satura, [, p, fas, association, ##io, ##hichobservationalstudies, ##writing, hd, ##23, ##missiondir, ##biomarkers, ##timatehazard, this, 230, ##dianfollow - up, ##usa, department, wide, ##del, 1, vanderbiltuniversitymedicalce, included, ##ty acids, ##used, ##yourintendeduseisnotpermittedbystatutory, ##bol, exposure, weidentifiedmultiple, mi, ##ons, ##foundingandreverseca, ##of, ##9, mr, ##asmasamples, ##icateif, ##mark, tri, cox, abnormalities, ##so, ##association analyses, ##decisiontosubmitthemanuscript, ##thor, ##mar, ##au, genome, 2, 410, ##al carcinogenesis, cr, ##bank, ld, ##bystatutory, ##inpl, lipoprotein lipids, ,, densitylipoprot, ##ubmitthemanuscri, cis, metabolic biomark, ##cr, using, ##yourintendeduseisnotpermitted, pre, low, ##in, ##nce, ##werem, ##gus, ##moncancer, ##interpre, ##fat, ##di, ##c, energy metabolism, ##uk, colorect, 21, 30, associated, , 143controls, published, ##ization, nuclearmagneticresonancespectroscopywas, ##oprotein, ##107, 143contro, ##fa, ##lipoprotein, improv, ##colorectal cancer, ##yslipide, ##ted, conducted, metabolic, ##for, colorectal carcinogenesis, ##oprotein abnormalities, ##time, ##107, ##tivecommonslicenceand, (, ##ac, britishjournalofcancer, british, fa, is, several lip, two - sample, analyses, ©, introduction, ##7, several, ##bolomics, ##ian randomization, ##cer, toes, ##tur, ##and, ##tos, ##bed, 4, vanderbilt - ingram, ##ian, ##omics, 14, 473, ##bu, investigate, ##tain, ##par, metabolic biomarkers, ##com, ##24, ##ost, proportional hazards models, ratios, ##f, ##using, ##ses, fang, youwillneedtoobtainpermissiondirectly, as, biomark, cox proportional, weidentifiedmultiple crc, ##cca, ##orotherthird, ##ologic studies, ##lsofeur, . 7year, 732, ##y, ##toquanti, large, ##genome, meta, metabolic reprogramming, men, ##dm, random, ten, ##97, ##cision, studies, ##criskwithpercentagesoflinolic, color, ##orexce, ##id, 420, elevated, 199, ##lip, ##un, altered, shu, regulationorexceedst, ##per, decreased, ##gulation, ##78, 473, 202, ##ofhi, ##2025, ##ect, ##formed, lip, approach, ##lev, increased, ##ame, ##smallnumbersofparticipants, density lipoprotein, ##vernovelbiomarkersfortargeted, ##lipide, ##tof, ##tow, hazards, ##marystatistic, regulation, bio, d, f"
A (29).pdf,"patients, Stroma, BRAF, SARIFArepresentstheH&E-basedcounterpartofanaggressivetumor, stage II patients, DoMore, neoplasms, patient, JNK, UK, Cancer, CRC patients, ofsome, p=0.650,hypermethyla-, Theimagesorotherthirdparty, gui-, AstraZeneca, gastrointestinal, TheAuthor(s)2023, stage II, Cancer Control/Tumor Node, GS, DNA, Sutterella, CRCs, BM, NHS, stage III, tissue, cancer, colorectalcancer, CRC, creativecommons.org/licenses/by/4.0/.","##sis, ministry of education and, ##alaffi, crc, disease, ##at, kaplan – meier, ##images, ##he, ##gno, 4a, higher, ##nk, provide, and, if, ms, ##bra, ##roma, & e, evaluation, ##pres, ##ty, iii, ##ando, progression, ##totheori, ##ssuchasco, ##nsen, ##alink, ##95, cancergenetherapy, ##l, the, ##bystatu, free, hat, dance, appropriate, ##orotherthirdpar, ##use, st, ##achessuchasconsensus, e, ##oth, ##h, ##base, negative, based, t, easy - to - other, 69, ##ricanjointcommittee, h & e, ##forrefinedpati, ##hylati, year, microsatellite, ##fference, man, ##haracter, tumor, ##sw, over, ##lu, ##ase, tn, repair, ##asa, routinely, ##more, ##app, mis, status, for health and care research, h, heterogeneous, stage iii, ##erafindingsunderscoresarifa - status, materialint, partial, cm, ##rial, ad, . 8million, ##you, enabled, survival, ##mark, ##shavenoconflictof, mmr, stage ii, positive, ##the, competing, ##s, ##ache, b, really, ##au, nosari, ##germanacademicexchangeservice, cr, sar, ##oxyl, ##ricanjo, ##nse, ##appro, ##asanidealbiomarker, therapy, ##markerforrefinedpatientstratificationandnoveldrugdeve, 8million, on, ##in, tissue, decreases, significantly decreased, pro, evident, protein, ##ro, ##di, research, . 0 %, colorect, sarif, youwillneed, other, ##ina, ##counterpartofanaggressivetum, ##tee, program, 10. 4 %, ##ms, ##cc, ##fa, ##ents, upregulated, ##he5, ##rectly, hypermet, ##alcancer, ##aj, ed, creative commons express, easy - to - other routinely, diagnostic, ##ma, survival endpoints, gui, ##ginal, stage, rapidly decreases, ds, surgical treatment, ashe, 2023, ##its, ##and, ##tis, specific survival, ##as, dependent, survival (, ##m, est, ##bio, 90 %, t - stages, ##com, clinicopathological features, ##dontheame, ##istic, ##under, ##indicateifchangeswerem, colorectalcancer, ##f, ##eth, ##beobserved, ##sus, biomark, ##if, ##psand, rapidly, could, bacteria, ##is, crcs, neoplasms, ##ti, partly, meta, ##ere, ##ment, ##nosignificant, deaths, cancergen, ##ndeosin, ##sta, os, ##nideal, j, ac, group, least < 0, gui -, ##v, ##mat, ##thecreative, ##ded, or, cb, honor, assessment, biomarkers, robust, tc, bra, open, ##f v600e mutations, event, ##ab, ##resarifa - status, ow, domore regulationorexceedsthe, high, ##poor, positivity, gene - expression - based, ##a, species, ##ctive, sarifa, ##tre, - y, ##wise, ##tu, analysis, bio, gene expression signature, ##ught, leading"
A (3).pdf,"colorectal, stool DNA, SiegelR, Rho, rectal cancer mouse, MAPRE1alone(P¼0.0007foradenoma, Texas.5DepartmentofInternalMedicine, Colorectal cancer, Cancer, colorectal cancers, likelihoodratiotest).The, P<0.0001foradvancedcolorectalcancer, MAPRE1, SOD1, P¼0.0003foradvancedcolorectalcancer, adenomas, P¼0.0025foradvancedcolorectalcancer, ReyJF, colorectal cancer tissues, adenoma, colorectal cancer mouse, fecal, Z. Feng, colorectal cancer, human adenoma, plasma samples, rat, colonic tissues, CEA, colorectalcancerandSOD1inadenomascomparedwithcontrols, blood, precancerous colon tissues, P<0.0001fortotalcolorectalcancer, colorectal cancer tumors, tissue, Q., cancer, colon adenomas, colorectalcancer, earlycolorectalcancer, JemalA.Colorectalcancerstatistics,2014.CACancer 3, BretthauerM","cea, 0. 731, ##de, ##yield, ##antly, ##0. 793, ##tet, ##ectalcan, advanced, ##leadingcauseo, ##color, ##oth, ##isementin variable, ##al cancers, ##er, ##isa, humanbiologyandpublichealths, ##x, found, ##result, ##pl, ##ea, cl, ##mark, but, ##so, biomarker, , ormaterialsupport, ##re1alone, ##cofthetwobiomarkers, blood, ##rford, ##su, ##articleweredefrayedinpartbythe, colorect, ##his, plasmamapre1, 1de, ##lowe, ##iv, stage, ##tal cancer, fc, ##nb, ##inthe, early colorectal cancer, ##her, ##gh, ##sol, ##denomascompared, ##while, com, ##mo, mapre1, ak, ##als, ##ect, chemical, ##menand, ##al cancer tumors, ##stool, ##ca152746, ##wer, colonoscopy, ##scompared, 10, ##at, we, ##son tests, ##pres, ca, ##co, ##enotic, ##achcolorectal cancer group, - sion, ##topromotecellmigrationandinvasionincolorectalcancer, ##uni, ##oma, combination, colon adenoma, ##to, ##colorectal, ##combination, ##mento, ##amine, ##bet, ##ofoundincrease, <, ##ssion, ##e, ##anadditive, ##invasive, ##es, ##d, ##cie, ##testsf, ##alcancerands, ##au, colon tissues, ##sitivityinthisst, induced colo - thecostsofpublicationoft, pre, ##inear, ##comb, ##¼, ##5 - year, ##boththeadeno, ##pre, detecting, ##ity, third, ##ma, ##andhasbeen, ##forqualityassuranceincolorectalcancerscreen, 66, page, adenoma, ##01, ##cer, ##hichan, ##previouslycharac, ##as, ##with, ##ize, ##if, ##elevatedinbot, distant, 2015, ##ele, ##thatmapre, cancercenter, ##art, ##eldedthehigh, biomarkers, lassologistic, ##ter, ##malevelsofmapre1, healthy controlgroup, 2, ##tp, colonic tissues, 45, - fe, ##effectoft, ##edetec, ##together, ##thatofc, ##he, r, od, map, the, mouse, ea, plasmabiomarkerfornasopharyngealcarcinoma, early, ##iot, based, colon, 9, ti, grantsupport, ##fi, tab, ##creen, ##ing, ##signif, ##ination, ##sinplasmalevelsofclic1inprecl, ##sit, ##tibodieswereprintedonthemicroarrays, ##of, ##t, normal, ##alone, ##po, ##pretationofda, ##translational trials, obesit, reduced, occult blood test, tissue, approximat, clinical, ##pre1, ##ina, texas, ##mapre1, ##wo, ##ymentof, - date, ##ebymarkeda, ##for, specific, cancers, ##oft, ch, ##no, ##ance, ##was, ##ear, ##owing, ##regre, ##cting, ##bu, ##mapre, ##hi, . 0025, ##erine, ##colorect, plasma, healthy controls, meta, ##ere, stool, ##al cancer, ##wereal, ##ex, ##al, ##1ex, withhealthycontrols, 3d, ##tthereforebe, ##sensitivity, ##ls, ##ely, sod1 protein expression, ak1, and, ##ceayieldeda, fe, tality, ##tha, colorectal cancer, ##alcancerandadenoma, ##ete, ##stasis, te, likelihood, colorectalcancersw, ##uc, cancer, this, orb, increases, ##cal, ##vate, ##od, 13 %, ##icate, ##95 %, ##ofmichiganmed - binedwithafecali, ##by, ##can, ##the, localized, dna test, ##w, ##epart, ##ade, plasmacealev, research, ##onofearly - stage, ##curable, imperiale, over many years, ##vert, ##ncesd, ##rdeathi, 95 %, ##tri, ##ford, 5, 91 %, ##mus, ##lo, in, ##0. 400at, ##eda, university, ##ta, ##lasmama, ##int, ##its, ##plete, ##and, ##cancon, human adenoma, ##ificantly, rat, ##ability, ##othermachinelearn, colon adenomas, ##orcolorectalcan, study, ##cea, ##lycolorectalcancer, icantly, ##bly, ##tovisual, ##ad, ##ized, aden, european, most, guidelines, ##u, rec, color, ##lycolor, ##pa, proteinex, ##1, ##than, ##contro, ##i, ##lev, ##pre1would bed, ##andear, ##th"
A (30).pdf,"microbiome, colorectal, TheStateUniversityofNewYorkat, sig-, weak-, TheSixthAffiliatedHospital, colorectal adenoma, adenoma, samples, LPS, USA.4StateKeyLaboratoryofOncogenesandRelatedGenes, ShanghaiJiaoTongUniversitySchoolofMedicine, gut microbiome, People’sRepublicofChina.5SchoolofMedicine, US1, adenoma-cancer, colorectal adenoma patients, QIIME2, cancer, adenoma-specific, colorectal ade-, CRC","##16srrnase, time, crc, – 15, ##sho, 43, enriched, 0, ##de, we, -, ##ug, 8th, he, processing, new, bioinformatics, obesity, ##single - cello, derived, ##gra, schooloflife, ##toadenoma, guangdong, colorectal adenoma, can - leave - one - dataset - out (, the, reads, ##thed, center, markers, inflammatoryboweldisease, ##tha, control, ##∆, microbial sequencing, ##tt, ##oma, plottedvalues, multiple, heptose, car, ##geststhattheelevatedactivit, 021, ##jia, ##cinogen36, validation, sequence, over, ##ese, tumor, ##rquantificationsofbacterialgenesintheadp - h, adenoma - control model, ##areqrt -, ##asa, ##are, ##nos, rt, ##gun, ##rel, ##ativeabundanceofcandidate, h, ##antenr, ##sitysch, ##fr, key, quantitative, ##ome shotgun, ##gen, ##osehasbeenidentified, pc, ##wed, ##of, ad, to, ##cies, ##graphicinformation, au, ##d, linked, lo, ##the, alterations, ##arkerscould, cr, ##p, microbial, quantitative insights, ##lyde, weak, ##guang, ##nthesis pathway, ##oton, ##iver, ##cr, ##sy, - 2, ##ep, ##in, ##andtocrcs, 13, ##ign, nf - κb, 217, ##authorsjointlysupervis, departmentofcolorectalsurger, 1, 800, 000, 4sta, co, ##dur, ##donginstituteofgastroenter, ##ccomp, 252sam, different, ##oft, ##lab, adp, depth, ##fo, ##p - heptose bio, ##shan, ##bial markers, analyses, us1, adenoma, κbs, ##7, ##cer, ##ub, inconsistent, ##and, 85, ##pment, ##on, und, ##pt, ##k, 7these, while, 306, sig - study design, ##school, 16s rrna, ##hebiosynt, ##ji, ##bacteria, ##thes, real, lp, ##ho, harvardmed, ##ad, environment, meta, micro, ##bial, ecology, ##ich, aden, ##ment, ##mo, ##provincialkeylaboratoryofcolorectalandpelvic floordiseases, ##n, 23265, ##edthisw, cers, ##ions, tfinding, studies, ##eb, color, y markers, olorectal cancer, - cancer, 860, 000 deaths, school, tc, 89, ##hesis, 2, 76, ##ience, healthy, shanghai, increased, ##ectal, ##lde, sequencing, 3d, universal, ##tu, sustained, do, ##ag"
A (31).pdf,"patients, early-stage CRC, HCs, tumor, CoreFacilityofInstruments, liver, serum CEA, TMT, NationalCancer, sig-, lymph nodes, pro-, serum carcinoembryonic antigen, CRC patients, NM, Fig.1, f
2, ChineseAcademyof, fic, lymph node, NationalCancerCenter/, LNM, urine specimens, CA19-9, c
7, F
C, FIT, CEA, e e B p r r a o d t f e o i r n d w, tec, C, vit, PRM, cancer, rd, CRC","cea, improved, crc, l, ##mm, 92 %, x, 0, ##de, ##rot, ur, r, 14 %, – 73. 5 %, and, ##vorte, ##mt, ##urinary, ##ate, 3500×gfor30minat, ie, ##hc, ##region, ima, ##ey, fe, u, the, ≥, 96 %, e, 65, ##weremi, ##edsamples, ##h, t, o, le, tmt, p, . 5 %, ##fle, ##suspendthe, car, sis, ##fi, 9, ##henquanti, ##vised, ##gfor, within 6 months, ot, ##protein, ##biomarkers, cancer, ##ur, ##ing, ##wl, ##ese, ##dis, 55, tumor, w, computed tomography, ##t differences, liver, vi, ##plewascentrifugedat, 1, mis, ##inary nancy, fit, h, ##hysiologicalchangesindifferentcrc, ##toreliablydiagnoseandde, ##ure, en, ##of, ##sam, ##t, red, fo, metachronous, c, ##ng, ##lter, ##d, 7, ph, ##dsamplesfromeach, ##withlnmandsynchron, ##2, ##ct, ##by, ##cino, ##can, testing, biomarker, signature, ##the, b, ##s, ##group, ##ffer, ##ence, cr, ce, ##forproteinscience, 1st, ##ry, antigen, ##sc, ninerandomlysel, zhaoxh, ’, ##cr, metastatic signatures, 91 – 97 %, tec, m, ##extractedbyac18extractioncolum, es, y, clinical, ##su, n, nature, ##4 h, ##di, fi, ##c, th, ##tment, ##sp, 30, ##sinthedotblot, ##xedsamplefr, ##gand, three, poor, sex, 13 o, ##91, ##×, 95 %, ##ne, ##tek, 24. 8 %, ##tm, 5, chinese, ##pleswas, yo, ##roupsw, ##lab, (, national, andair - dried, aided, ter, ct, 1 e, ##a -, ##int, embryo, age, 4, ##key, ##re, ##m, 10th, g, ##51 %, hc, ##allymp, 3 n, –, ##par, death protein, ##ntwascollectedandt, 1 o, i, ##teome, na, 8, followed, static, biomark, study, qualified, ##tore, ##o, er, ##do, a, ##85 %, ##molecularoncology, balanced, %, ##ad, distant, meta, ##sive, imaging, ##ofmed, rm, ##dm, ##sta, ##n, ##patientswithoutmetastases, 15, 62 %, serum, 400µloflysisbuffer, . s, ##eo, distant spread, ac, significant, ##ly, sensitivity, 3, ##pa, ##with131tm, ##ous, olorectal cancer, ##g -, ##ded, io, ##pathop, ##per, 9th, ##pool, sc, 2, hen, high, ##orator, diagnosis - related, s, ami, ##centrifugationat14, 000, 3d, ##amo, aberran, ##cp, ##wer, ##thesupernata, d, ##thethree, si, f, ##patient, peptideswere"
A (32).pdf,"nuclear/cytoplasmic, streamtargetstranscriptsintheRNA-Seqcoculturedataset(Supple-, ToinvestigatetheroleoftheIL-1pathwayincolonicCAFs, tumor cell spheroids, F.Managementof, co-cultures, breast cancer tissues, studieshaveturnedtowardssingle-cell sensitiveandresponsivecellsinCRC.HighIL1R1mRNAexpressionin, confirmingitsabilitytoactivatetheNFκBpathwayinCAFs, podoplanin, single-cell, TheAuthor(s)2023, CRC patient samples, CLZ, collagen, CAFs","##forthestudyofthetumors, fig, crc, ##loe, ##orexceedsthe, -, ##de, ##tum, ##fromthecopy, ##serveda, ##ghil, ##l, ##u - single - cell, mycafsandicafs, ##oth, ##ind, ##incafsbytumorcellsleads, two, ##pressing, ##ema, ##x, ##withtumorcellsquanti, ##1r1m, ##theoth, ##ide, tumor, ##used, ##nesecretiontriggered, cl, ##thenfκbpathway, to, but, ##yourintended, culture, additionalinform, ##ermissionsinformation, ##well, supplementarymate, ##nco, ##bystatutory, ##nse, ##activa, ##ep, ##ratedit, ##single - cell, ##ctivation, breast cancer tissues, ##κb, ##fs, ##fo, ##il1r1, is, sw, ##xpressionof, ##has, detect, ##inca, ##ion, ##uldbeaddressed, was, openaccessthisarticleislicensed, single - cellsequencinganalysisidentifies, ##f, ##her, ##gh, ##thi, inflammation, ##sive, ##sandp, caf, ##crcsingle - celldatasets, cultures, anacademichpcc, studies, ##eo, ##material, col, ##hicaf, ##gulation, ##eadyabas, ##culturedataset, ##lke, ##wereeitherisolatfu, ##blisheddatasets, ##lagen, observed, indicated, ##otherw, podoplanin (, extremely, ##type, ##bytheauthor, treatment, ##samples, ##at, we, if, ##genee, ##co, activationoftheil1 -, ##nding decipherscellt, fcytoki, ##uded, with, ##underacreativecommons, ##to, ##previouslypu, ##var, gel, ##bet, ##orcells, lee, ##il, ##questsformaterialss, ang, nuclearp65, ##es, competing, ##isavaila, ##rna, ##ourrna - se, streamtargetstranscriptsintherna, ##lcytokinea, ##mission, ##cus, , anonymous,, ##filei, furthersupp, ##fy, ##nownnfκbdown -, ##α - smoothmuscleactin, ##theincrease, ##ma, ##ac, ##ncreasein cultures, close, ##allthreedatase, ##as, ##with, ##imagesorotherthirdpartymaterialint, ##l - 1pathwaymembers, ##k, ##unpa, ##totumorcellsshowed, ##luster, single - cell, ai, ##hei, ##en, ##sti, ##withtwo, ni, ##strom, apeerre, sol, ##ly, ##ca, ##highhet, ##bution, ##due, ##proteomeprofilerhum, ##per, ##lice, 202, ##viewinformationnaturecom, high, ##reative, ##be, ##amo, pdpn, ##grown, ##gned, sensitiveandres, ##mun, ##vedthatfibroblasts, ##he, ##way, ##ionalclaim, ##pathway, ##cytok, ##queincafcharacteriza - thetumorstromacomparedt, ##nca, ##isspeci, ##pit, todissect, pronounced, ##levated measures, the, of, changeswer, ##tt, review, ##up, ti, ##fi, umorspheroidcul -, ##ing, w, ##rel, ##indicateif, ##ni, ##of, ##t, ##elial, ##intheart, ##toane, ##ule, ’, ##highestp, low, ##ps, ##matorynature, ##duced, ##ransitions, ##intoil1r1, ##c, ##ableinthreeadditionalpublicbulkcrcdataset, ##af, co, ##son, ##expression, supplementaryinformationtheonlineversioncontains attribution4. 0interna, ##icationsthanksfloriangreten, mal, ##for, seq, ##oft, ##xpress, ##was, ##willneedtoob, ##wereeitherpaired, ##ub, ##ioninfibroblasts, ##forth, 1path, ##wee, ##re, 16, ##on, ##ali, ##themultis, ##ykit, ##com, ##hi, ##tate, ##ole, ##pd, reprint, ##looril, as, ##ation, ##rect, ##r, ##fl, men, sub, ##cells, ##withre, ##ble, pathway, caf -, α, ##ex, ##ha, ##und, morerecent, ##sma, increased, il, ##eit, ##ls, thee, vicinity, ##rra, ##am, tures, and, split, inca, fibroblast activation protein ( fap ) 8, cell spher, ##ando, ##tro, 5art, ##orted, ##umber, ##tha, ##r1, ##acreditlinetothemate, ##express, ##press, ##ser, expressingcelltype, single versatile, ##an, visit, 1, ##65n / c, ##are, included, ##usedthetcgabu, ##14, ##veturnedtowards, ##ala, clustered, sequencing library, ##βstimulation, ##fe, 1a, ##tom, ##lypublished, ##by, ##the, ##how, ##sin, ##icle, distribution, ##in, ##mons, ##acopy, ##di, tumorfibroblasts, ##il - 1pathwayasakeyplayerincoloniccafs, myofibroblastic markers, license, ##inn, ##ef, co -, ##zed, ##eakeytech, ##ob, ##lo, ##ired, in, ##eda, ##incol, ##hic, ##int, ##nti, ##its, ##and, ##is, ##cel, ##pro - inflammatorycytok, ##hian, ##tainper, ##meontheresponse, ##pee, ##gate, ##ions, ##inessecretedintotheconditionedmedia, ##eres, ##yse, ##q, ##mainca, ##il - 1, ##ther, ##1, ##significantincrease, ##formed, αsma, use, sequencing, gene expression, il1r1"
A (33).pdf,"patients, TP53andchr20qamplifications(SRC, AS B m R u A t. F mut, g d e u n le e s M, bevacizumab, BRAF, FAM123B, T cetuximab bevacizumab, adenocarcinoma, leucovorinandirinotecan(FOLFOXIRI)backbone, EGFR, Fig.1|TheOncologyBiomarkerDiscovery(OncoBird)workflow.aPatientsin, T, BRCA2andNF1did, ATM, RAS wild-type tumours, left, oxaliplatin, Cetuximab, CMS2 tumours, b, ARID1A, Bevacizumab, TOP1, Cell, somatic, M.W.TheroleofSrcin, BRAFalt/KRASalt/NRASalt, T cetuximab, FOLFIRI, tumour subtypes S, NRAS exon 2-4, tumours, cetuximab, M.Wild-type, tumour, Supplementary Fig. 9, LRP1B, CMS1 tumours, layer","dnatopoisomeraseiisacofactorforc, ##vrus, ##mab, ##with5, ##tionone, ##rialfundingfrommerckkga, ep, -, ##tumour our, 0, epacs, enriched, ##pser, ##iri, ##fromrochepharmaag, ms, ##falt, left - sided, wild type, ##2amp, ##tum, 410, mcrc, ##l, flu, for, ##ind, ##eal, p, ##ackedbenef, ##analysis, were, acizuma, ##x, 50, left−, ##regimenswithmeas, ##atments, geneticbiomarkers, 0 −2 −1, ##ste, to, ##cies, h i, 100 % + + +, ##mark, ##tic, ##had, ##2, ##vacizuma, b, folfoxiri, 4100 %, ##byprojektdeal, left−sided, ##lighttheaccessi - signalling pathway, cetuximab, ##metastaticcolorectal, brafa, ##nf1, es, ##ite instabilities, sided, months, ##uso, ##iriplus, 25 50 75, ##ome, ##ured, ##fo, ##®, ##theeuropean, la, ##f1mut, ##ras, sr, ##lon, ##ncinganalysis, ##f, ##zard, ##bf, ##cetuximabversusfolfiri, ##ape, alterations months, ##ura, nras, ##sing, /, ##scapeacrossmultipleclinical, such, ##tumourmutationalburden, 3, theoncology, genetic sequencing panels, 0 1 2 better, ##ional, egfr, ##tre, nc, type, ##tu, ##wer, ##mour, ##20, ##ed, f, ##type, ##col, treatment, sho, we, +, coloncan, ll o, ##hc, juninthe, ##xi, ##dnal, ##ucovorinandirinotec, ##bina, ##to, llare, pi, ##rasal, germany, wasreflected, tumour, - sided, 100 months, ##asa, treatment arms, ##nf, ##vi, weleveragedcox, servedonadvisoryboardsforbmsand, ##d, competing, time - to - eventdata, ##rity, ##thebiomarkerland, 75 %, ##by logistic regression models, kr, de, ce, ##p, ##11 - 4, mutations, bev -, quan, ##binaryvariablescapturing, ##side, eneg, ##2mcrc, 25, molecular, ##uding, ##taandodds mol somaticmu, ##alt, ##tuximab, ##arevo, ##ma, them, ##ac, ##rich, ##7, ##ignificantly, ##fan, orectal expression, arms, ##ost, ##high, eatment, overallor, ##bird, ##olfiri, mia, ##ut, tp53andchr20qamplifications, a, micro, ##mourdna, ##en, nrasa, ##sa, grenzach, ##tions, re, 75, ##survivalda, wed, ##ben, ##vo months, ##bution, disc, ##bygeneticalterations, explaining, 100 %, ##be, cetu, 50 %, d, ra, ##intervals, ##may, ##biomarkerdiscovery, ##fire, lavivrus, ##he, r, ##unda, author, ##andclinicalcha, progression, ##vacizumab, ##opeanunion, krasal, wildtype, ##lt, ##csdna, ##tumoursubtypesbase, ##kramoib, 0 %, leucovorinandirinotecan, the, findings, u, twotreat, free, ##gre, ##fied, lrp, ##aisaprognosticmarkerincolorectal funding, backbone, t, ##ofcetuximab, ##did ratios, 75 100, ##fi, randomisation, 0 25, brca2, subgroup analyses, 30 %, ##indicatethedatain, ##s1 tumour, tore, ##ase, right colon, 75 % + + wild type, ##75, ##eros, ##40, ##ni, ##of, ##t, ##hon, plus, ##s, tneitap, ##cancer, fam123b, somatic mutations, ##bot, ##andcms2, s2, 25 0 %, s1, ##rydatain, ##vac, m, ##cess, clinical, ##uomut, ##ati, ##herele, ##ina, g d, ##nt, onco, ##ents, ##®baseds, 52, ##ft - sided, ##ar, ##kin, ##1mut, ##oft, ##no, tu, ap, ##ear, ##vivrus, ##re, g, ##gene, ##udy cancercellproliferation, unstratified, ##cm, kras, as, ##tionof, nr, irs, 50 % + + + + 25 %, ##isexem, mo, + + +, stint, top1amp, 0 1 0 0 1 0 1 0 eludom, ##or, s m, ##vo, 75 % + + f, krasalt, a m, ##l simi, bra, ##al, between, molecular characterisation, k, - be, 100, tell, increased, ##tumours, s, + 0 %, ##wereenrichedin, ##theprevious, braf, ##lu, ##em, ##btr, ##le, thee, ##ls, ##ged, 50 % +, ##masterpro, left hemicolon, ##80, wild, 2 fdr, ##olf, 4 : 5391, ##ft, e, ##drivermutation, plain, ##ersforcetux - tumours, ##oor, le, o, ##amp, ##tat, mutationsin, ##uc, ta, ##an, ##clinicaltrial openaccessfundingenabledandorganized, both, ##out, 1, ##are, ##3, ##cal, ##fr, freesurvival, ##om, cm, ##95 %, so, ##can, ##the, s2 s1, ##ray, alterations, ##ast, v600, ##in, ras, n, aurora, ##ssed, ##ours, ##uta, ##ms, oxalipl, ##effectsizesbyhazard, ##izumab, char, ##tri, number, ##ximab, top, (, ##arm, genetic biomarkers, arid, ##int, these, ##43, ##eque, ##and, ##vance, ##pt, ##earchcoun, ll, ##ap, ##using, ##res, primary, right, received, lacinilc, + 0 25 50, ##cel, atm, ##richedinbot, ##ci, mutuallyexclusivegenemodules, random, weemplofunding, ##ce, j, ##lines, objective response rate, basedmic, ##asalt, altered, ##1, ##right - sided, be, right - sided, confidence, retrospective, rcts, ##birds, epa, brafalt, + + + 0 %, ##patient"
A (34).pdf,"extracellular matrix, tumor, S100A8, tissue COL12A1, plasma, EGFR, CD8+Tem cell, sig-, RHO, cellular matrix, TCRsignaling, CRC patients, MAPK, THBS2, COL12A1, cellular, enrichmentontheDEPsofeachgroupaccordingtheCPDBmolecular, Neutrophil, EGFR-, ECM, iron, ECMproteoglycans, tumor tissues, G-I, VEGFA-VEGFR2, S100A9, wescreenedforapanelofpro-, cetuximab, FDR=0.03, 2024)1 5:980 9Article, tissue, SNSG","980, ##mab, crc, ##sho, ##ivation, ##markerforanti - regulatorsinvolvedinthes, 0, ##de, -, gene set enrichment, database, ss, interaction, ##hat, ##patientsmatchedwith, although, ##teinsand251, protein - protein interaction network, ##treat - ofthe, ##l, ##ocetux, proteomics, connection, ##aran, ##markers, med - 5, wes, ##analysis, ##protein, gradual, ##ide, teins, 17, ##dis, tumor, regulated, mali, 26, ##pl, presented, ##frisexpressed, h, ul, ##used, ##md, confusion, ##asmas, ##heseb, ##rovedoverallsurvivaland, to, ##ng, ##rasmutations, but, ##ct, ##had, ##2, ##so, ##groupac, cr, ##arefoundin, ##ep, ##sars - cov - 2, ##su, ##carcinoma, ##asthe, ##uld, ##fromcrcp, ##care, downwardtrend, ##mmuneact, naive, mapk signaling pathway, exhibited, ##fo, ##ass, ##ns - sigproteins, upward, ##con, including, ##furt, ##mate, ##inthe, ##ras, extra - int, female, ##f, more, ##im, ##her, - ii, thus, responses, ##gative, 287a, ##mo, ##cantlyincreasedinns group, ##cera, such, ##herap, col, tc, 20, ##ect, proteins, ##gnantlymphoma, ##sfromhealthycon, ##a, ##tre, enrichment analysis, ##tu, bio, ##wer, ##forglycol, ##ed, ##type, ##tumortissues, ##col, ##consensusclustering, at, we, ##pas, ##byrh, ##og, ##eva, ##745, iii, ##zedclin, differentiated resistance, onto, ##hc, ., thbs, ##ark, ##xi, 12, ##ec, 0. 571b, ##it, score, ##veda, ##to, ##la, ##b, collagen - samples, ##teinsin, ##mp, lungc, ##pro, <, distinct, ##rc, ##ting, gender, ##ximabt, ##eaanalysis, ##uis, ##h2232gp, independentintracellularsi, initial, ##ot, ce, ##ise, ##p, esophagealcancer, ##pase cycle, ##cr, therapy, ##27 proteins, ##lativelyhighoverlappedproportion, ##pp, rr, randomized trial, theotherras - relatedsubfamilymembers, ##ssgseapathwayscore, th, other, s100a9, ##oththe, ##progression - freesurvivaland, ##ted, vegfa, ##ma, different, ##bha, treated, ##dt, ##predictive, ##patientswithkras differentiation, ##7, only, ##cer, ##my, ##dictive, ##cin, ##as, ##27paired, ##with, ##us, ##bio, ##ponded, ##mut, ##ink, ##100a8, ##kras, ##fb, %, four, icaltrials, ##en, ##markersofthefi, ##other, ni, ##three, gps, ##ly, vegfr, 235, biomarkers, ##per, ##ter, ##epsidenti, ##31, 2, ##tp, rho, ##mutations, isub, ##omi, cetu, pv, tumor tissue, ##amo, 11, ##asantigen proportionofcd8 + temcellshowedasi, ##ues, poorlydifferentiated, ec, ##si, ##he, 0. 232b, ##sb, ##ss, there, the, ##yin, ##not, ##fied, ##itia, amplesfromcr, ##ofproteomics, ##mabimp, ##qualityoflifebetterthandidb, ##up, ##fi, ##ofindpot, ##lative, ##anal, ##ase, proteomic, ##uisht, accuracy, ##of, cellular matrix organization, . 5, proteomicanalysis, enrichmentont, 7, ##um, ##s, ##cancer, ##fc, ##hes, ##po, ##iationofpathways, increase, correlation analysis, tissue, clinical, ##tivecolitis, ##minetheass, mapk, ##ati, an, egfr inhibitors, ##ina, results, ##sul, ##and7452gp, signaling, means plot, ##ne, ##for, ##dother, gt, potential, ##oft, ##ssgs, ##xpress, tumor size, ##was, sampling, ##hed, ##alue, ##ub, ##patientsat, ##tis, ##forth, g, ##com, cellular expression, ##wedfourproteinsco, resistance, as, 8, ##asma, ##gastriccancer, extracellular matrix, anti - egfr, ##alingpathwaysmight, plasma, ofwhic, gsea, ##ti, men, 146, bladder, among, strongly, pathway, downward, ##apanelofpro -, ##id, ##rras, ##erespecifically association, cd8 + tem cell, ##nat, between, ##ach, ##und, enriched in, k, sensitive, s, ##fourproteinss, well, ##cp, ##lu, ##ls, ##rra, and, ##mas, heterogeneity, wild, ##tha, e, multiple courses, ##cessar, ms - based, ##thesepro, ##uldwelldisting, ##thedynamicoft, ##main, ecm, ##tumor, 69, autoimmune diseases, ##ser, ##negativecorrelation - sig, – 60, ##sw, 1, ##are, male, . 8, ##over, ad, ##fe, ##significantenrichmentofthesepathwaysinthen, ##−40 %, positive, ##the, ##pon, mediated, breast, ##umortiss, ##85, ##ast, ##in, cetuxima, ##coll, da, ##creened, n, ##multiplecourse, ##ces, ##down - regulated, gseawith, ##rand, ##imabt, ##esignatures, ##sbeenproventobeeffectivefor, ##ding, malignant diseases, (, ##ein, 9art, crcpatien, ##heproteomeprofiles, 5 :, ##swith, ##and, ##m, ##tuxi, ##vance, activating, ##ap, ##autophagywereenrichedinthesen - tion, g - i, ##ses, ##ntified, it, ##res, regulatedintumortissues, ##ponset, ##eg, ia, ##ad, matrix, ##hatthed, ##s - sigprotein, ##ren, tissues, ##ce, group, significant, ##sidentified9258, s100a, ##ro, degree, ##asmall, ##formed, ##tlynegative, preserved, ##theses, si, ##patient, ##sistente"
A (35).pdf,"serum TFF1, Training/Valida(cid:2)on + 5, plasma PZP, whenusingtheaverage-riskadultsat, ComS, colorectal cancer, PRS, TDI (, ProS, beta-binding protein 2, tissues, Table2).Theagesofparticipantswithlow-,medium-,orhigh-, historyofCRCandwithout, CRC","##risk - adapted, crc, riskad, -, ##fen, ##de, ltbp2, 60, ##pop, ##cost - 50yearsoldwhic, ##benefit, summary, effectiveness, ##passed, 05, ##sonalizedinitialscreeningage, familyhistoryofcrc, 0. 0, 2006, ##teinlevelwaslinkedtopoorover, veproteomics, ##wasobtainedfrom, limited, proteome - widedifferen, p, tff1, whereas, two, were, - yearcum, ##er, ##hos, year, ##pl, ##ve, ##ea, oteomics, ##ving, ##tic, int, ##2, binding protein, medicalhistory dataset, model performance, cr, equivalent, ##pressed, 243, on, genome - wideprs, case, ##bysexandage, ##elofpz, ##his, < 0. 05, ##delandrisk - adapted, ##forre, ##ts, . 5yearsearl, ##equalto, ##fo, ##thanparticipantsinthem, c - sta, process, old, ##tingage, coxpropor, neoadjuvantchemoradiation, ##cogenein, ##sen, . 9, ##f, ##im, extensionassay, ##eshave, ##combined, polygenic, ##gh, ##sol, ##alandcon, ##san, ##act, nt, ##high - prs, com, risk - adapted, ##mo, ##n, ##rapandabsoluterisk, 0. 100, ##lof421differ, ##pr, ##star, ##tpartici, 51, 500contro, ##level, proteins, ##ula, ##ancer, ##ed, serum, f, onstage, 0. 075, ##thescreen, ##olo, 10, 0. 050, net, ##averageriskatage50, ##ert, we, ##cs, ##trols, +, ##inga, rap and, pzp, ##lowgrouptobe46or ethicsapprovalforthedisco, ##issues, ##vival, ##thed, ##pression analysis, ##ier, 7 : 3, 150, without, ##b, ##hea, ##pro, ##non, ##asa, ##crccases, ha, ##adultsat, ##d, median, cox, qcancer - 15, ##lticenterresearcheth, ##rim, ##ip, ##p, valida, ##cr, drinking, pre, + 5, ##pp, ##ity, reached, ##rsityschoolofmedicine, ##year, pr, ##nor, late, matched, them, 57 years, ##udi, ##as, proteinriskscore, ##with, 0. 000 0. 025, ##qua, ##high, < 40year, ##alhazardsregression, risk threshold, ytivitisnes, ##udy, er, risk, methods, ##culatedsubsequently, crcincidence training, ##tto, generalpop, ##rov, ##ca, ##scommitteesofse, ##cross -, ##per, 53, ##ter, ##yearslater, high, disc, adapted, ##du, ##ues, ra, ##ump, ##he, ##r -, higher, ##val, ##stageofthisst, ##themrnaleveloft, riskac, ##13. 05year, < 0., the, risks, ##participate, >, t, proteinbiomarkers, ##iod, 0. 015 0. 010 0. 005, ti, ##ofdiffer, burden, circulating, ##differentrisk groups, ##creen, ##ing, protein biomarkers discoverystage valid, ##brillin, ##ages, ##app, ##ched, ##ukbb, ##of, ##mi, ##t, ##ptendedtopathological, ##16, 2021. 3, ##s, risk stratifica, ##fc, ##po, mesenchymaltransitionprocess, low, ##ff, ##alhazardsmodel, fi, ##c, ##ina, ##10, previous, ##maltissuesandpromoted, ##sea, 1 −, ##46year, ethics, screening, ##ncance, ##ele - vatedincrctiss, ##for, specific, ##risk - adapted star, ##oft, ldpred, ##was, 731incide, ##ris, clinical u, ##roupreachedtheequival, ##k ) methods, ##forth, ##8. 9, ##ture, ##ffi, ##par, ##com, ##sur, toparticipa, ##hi, ages, ##ej, ##ger, greater, ##startingage, ##tore, plasma, ##ti, ##partic, ##sta, ##riskscores, qcancer - s, ##cum, ##crc, ##ltbp2, olinkproximity, ##were, ##vancement, ##ex, ##ded, ##und, ##ntcase, ##crcs, 41 years, ##alignantbehavioro, 129, ##ls, ##le, ##ration, ##bloodproteomics, ##rot, auto, ##simul - proteomicsignatures, 0. 2 0. 4 0. 6 0. 8 1. 0 0. 1 8. 0 6. 0 4. 0 2. 0 0. 0 3 2, ##pe, and, 15. 2 years later, ##kwas, cumulativecrcriskequaltothe, ##oftheepithelial - the, alex, ng, qcance, 2010, ##tha, colorectal cancer, - yearcumulative, ##s,, ##10 - y, ##forparticipants, ##screeningageis, ##lthy, ##rviaactivation, - satge test, 0. 000 0. 100, this, ta, prs, ##ium, both, ##mal years old, 1, ##low -, ##hanthoseinadjacent, calibra, ##geneticandnon, ##report, ##cal, ##withprosinhigh, ##very, atota, ##om, aswellas, lit, none, participantsinhighcom, ##st, andrectalcancerpatients, -,, ##by, ##can, ##the, ##mt6, improved performance, ##10 - year, ,, ##z, qfin, se, 50con, ##tivecrcriskequaltotheaverageriskatage50, ##in, ve, ##low, ##ofscreening, ##ants, ##all, than, ##toberemarkably, ##17, id, ##plex, ethnicity, ear, ##ein, ##int, lass, age, ##rl, ##ages theethic, ##m, ##pantsinhighpr, ##estimating, ##por, ##lc, ##relatedtotheresponseto, ##levelsofltbp2incrct, ##y, ##ad, starting ages, decisioncurveanalysis, medium,, cs, 15, ##tl, ##growth, or, ##1, lt, ##than, ##i, ##lev, ##screen, ##riskscore, ##ght, folds, geneticfactors"
A (36).pdf,"patients, C T C T 2 5, UC, Colorectal cancer, T.D.L. Pathology, UK, Cancer, colorectal cancers, C C G G T T C C G G T T CGT CGT CGT CGT CGT CGT CGT CGT CGT CGT CGT CGT CGT CGT CGT CGT CGT CGT CGT CGT A A A A A A A A A A A A A A A A A A A A A A A A C C C C C C C C C C C C, cancers, formalin-fixed tissues, Cell Rep 3, head, endometrial, lqad005, C.L. Patient, C. D., CGT CGT CGT CGT CGT CGT CGT CGT CGT CGT CGT CGT CGT CGT CGT CGT CGT CGT CGT CGT CGT CGT CGT CGT A A A A A A A A A A A A A A A A A A A A A A A A CCC CCC CCC CCC CCC CCC CCC CCC CCC CCC CCC CCC TTT TTT TTT TTT TTT TTT TTT TTT TTT TTT TTT TTT C C C C C C C C C C C C T T T T T T T T T T T T AAA GGG TTT CCC AAA GGG TTT CCC AAA GGG TTT CCC AAA GGG TTT CCC AAA GGG TTT CCC AAA GGG TTT CCC A G T C A G T C A G T C A G T C A G T C A G T C, | Vol 643 | 3, g c e -u n n ic transcribed, Triton, G C, T T>A T>, cancer, human cancer, L.","mutational sign, 2 5 + 36, > 1 - bp, institute of health, 0, 1 - bp, 18 %, transcribed, ss, units, +, translational research informatics, 9. 8 7. 3 4. 9 2. 4 0 > 1 - bp, ##homology length, cc, mu, 36 %, burrows - wheeler transform. 1u01ca, ##12312345 +, ##gt, regression analysis, microbiomics, 12, head, metadata - driven, ##etion, 0 0, e, mixture model, cgt, fast, 24, >, t, 2025, neck, conventional, 72 %, ##formatics, wellcome, colorectal, 52 39 26 13 0 nature |, 231, mutation, end, ##ures, 1, ##trial, 123, epidemiology, vol, computational analyses, tt, c, bp, computing, 112, triton, alexa, the past, ic, ttt, ##nding, ce, 2. 1 t > c, wi, t > g g, gen, hierarchical dirichlet process, + 012345 + 012345 +, ##bs, cancer types, ##hering, san diego supercomputer center, |, . 2, e - u n, n, 51 - bp, del, kidney13, ##c, 1 - bp insertion, research, ##pre, assistance, of california, san diego, repeat units, pac, 18 % 36 %, uc san diego, cancers, tori, 4. 1, ##lab, short read alignment, egatnecrep, geographic plementary approach, ##al signature, consult, july, ##on, 54 %, g, sample, 48, dec, ##r genomics, ##al pro, detecti, advice, na, 123456, homopolymer length, aaa, ##o, a, - transcribed, repeats microhomology, micro, ##9, 10, ##456, 643, ##graphs, ##456 +, deletion, 3, e te n r i, ##gg, ##456 + 012345 + 012345 + 012345 + 012345 +, ##gatnecrep, repeats > 1 - bp insertion, a a a a a a a a a, 202, oesophagus, insertion length, ##tage, s, sequencing, formalin - fixed tissues, repeats, analysis, f"
A (37).pdf,"patients, thelial, Xenium Chromium, c e, intestinal epi-, tumor, Tumor REG1A STAB1 REG1A LCN2 SPP1 MMP11, Macrophage Macrophage Macrophage, anti-tumor macrophages, FFPE sections, B cells, Pixel-seq22, pro-tumor, CRC samples, single-cell, carcinoma, FFPE tissues, CXCL9, PRF1, colorectal adeno-, macrophages, macrophage, cells, Tumor, SPP1, Clonotype, STAB1 CXCL10 T cell B cell, colon samples, cell, Colon, CRC tissues, Chromium TCR, cellular, tissues, T cells, CXCL9 2, PERP, CXCL11, tumor biopsies, smooth muscle, Rectum II-A F, HDST20, b d f, Tumor Tumor Tumor, endothelial, intratumor, T cell, Goblet Tumor Tumor, Tumor E, CXCL10, CEACAM5, neuronal, Single-cell, tissue, cel- cial, GZMK Clonotype1_TRB, c e
, anti-tumor, cancer, myeloid, nuclear, CXCL9 CXCL11 Macrophage CAF
Fig. 7 |, TGFBI, fibroblasts, CRC","cxcl11, ##xcl, crc, l, max spp1, cel - cial technologies, -, x, we, single - cell reference atlas, jc, ##finding, 152, tgfbi, scrna - seq, go, ##tum, mutation - centered disease, ##acam, cxcl10, ##2 –, 151, liga, tcr, e, cluster, ##ge, serial, ib, single - cell transcriptomic, nova, hd capture, crc5, stab1, t, cxcl, tra1 /, tra2 /, p, cell segmentation algorithms, situ, high - resolution, morphological, 2035, hd, measurement, survival rate, f 72, cancer, db, sophisticated analyses, clonotype, trb, ne, mm, - sequencing, tumor, ##zma clonotype1 _ tra2, ligated probe, ##lenop, ##3, expression, h, barcoded oligonucle, macrophages, probe, macrophage segmentation analysis, 1521, ##5, cl, ##t, to, clonotype1, c, predicte, ##st, gene expression analysis, crc tissues, types, ##2, technologies, resolution, normal, ##s, pixel - seq22, b, demons, ndothelial, cr, ce, ##p, visium v2 xenium chromium flex, ##phage, transfer, cell nature genetics, se, open - st, adeno, |, ##c1p, ##n trac, prf1, nature, double, µm, ##c, max, th, other, cel, ##romium, three, poor, spatial, ##hai, min, ##zmk, macrophage, ##it - seq21, ##izes, features, local, ffpe, confirms, ch, squares, 9. 4 %, crc2p, sequencing - based genomic, ##um in situ, biopsies, het, visium hd, ##uronal, macro, visium, single - cell scale, reg1a, g, ##blet, perp, _ trb, i, immune responses, colon region, spp1, adaptive, nuclear, biomark, ##eni, 2 × 2 -, five, adjacent tissue (, reg, transcript, lcn2, men, 5 4 3, sections, cells, lcn, caf, deaths, 260, 506, ##crc, rec, ##ological, color, faithful, ##q, unknown, stab1 reg1a, t cell b cell, vis, ##onally expanded, cxcl9, ##1, sex age, availabl, between, 2, ##otides, 202, 2 1 0, high, ##p11, stab, ##a, ##ectal, inc, perp f, gene expression, bio, d, clonotype1 _ tra1, serial ffpe, f, c1"
A (38).pdf,"patients, breast cancer, HR, tumor, E. A., b High-risk stage II, Colon Cancer, Bayer, Cancer, E.O., ctDNA, Tie, resectable CRC, stage III colon adenocarcinoma, colorectal cancer, DNA, tumor DNA, colon cancer, E., AMEA, stage II colon cancer, urothelial carcinoma, CRC","##m -, dna, time, med, crc, l, ##ection, dna analysis, personal, 0, -, ur, 74 months, higher, iii, sufinding, 216, k - sample tests, 91. 5 %, ., 4 weeks after, 12, guided therapy, ci, e, 19, colorectal cancer, own, 24, ##ulate - japan study, t, colon, 84, high - risk, surgical, p, esa, 4 1. 00 0. 75 0. 50 0. 25 0 0 6, resection, follow, 13 3 0 62 61 53 28 0, act 219, lectures, 30 %, circulating, ##urrence risk, erapy, 4 weeks, dfs, full - time, society of clinical oncology, tumor, adenocarcinoma, tn, roche diagnostic, ##3, h, ##rence, stage iii, resectable, stage 2a, 32, 934 out, 97. 1 %, 91. 3 %, 1. 00 0. 75 0. 50 0. 25, ad, 131, = 0. 16 0 0 6 12, ##es, 6. 59, 95 %, 22. 0 %, stage ii, 98. 6 %, 18, b, since 2004, nippon boehringer ing, ##nding, cr, adjusted, breast, ##ected oligo - positivity, 28 out of 72, improve, 312, act, galaxy, – 70 %, 41, 94. 9 %, pre, |, stage ii – iv, 660, ##othelial carcinoma, chemotherapy, 2 number, ##c, agency for medical research and development, ##dna, th, ##ulate -, japan, hr, 21 7 0, colorectal - liver, ##urrence, lavi, co, ctdna, ##ical, ##static, ##se, < 0. 0001, 645, 25 out of 312, 5, postsurg, ##fs, d, ##iv, ct, tu, cal, stage, analyses, 95. 4 %, observation, la, 72, ##us, 16, ##m, ##11, ##vant, ##mour, ##vivr, i, ##sur, 29. 3 %, clinicopathological features, roche, january 2023, 9 4 0, as, posts, 12 out of 219, surgery, ##ectable cr, 7 %, ##rf, events, ##gh, 616 271, risk, res, meta, stage iv, ##ctomy, ##mo, 6, ##en, inferior, ##sta, 40, 127 – 134 131, . s, 87, rec, che, 209, ##id, 1. 71, 95 % ci 0. 80 – 3. 7, risk stage ii, 303, ##vr, 93. 3 %, 2, um, guided treatment, high, ee, contributions, 18m, hp, po, 291, nate, immunotherapy, negat, 65 48 26, 32 out of 41 observation, 61. 6 %"
A (39).pdf,"patients, E. G., bevacizumab, BRAF, l-leucovorin, tumor, triple-negative, panitumumab, EGFR, blood-, cancer patients, Bayer, anti-EGFR antibody, A. J., NRAS, RAS/BRAF WT, Patients, Panitumumab, 271c, mFOLFOX6, Ono, FA, left, oxaliplatin, ALK, folinic acid, AstraZeneca, Bristol-Myers Squibb, 5-fluorouracil, Bevacizumab, Plasma ctDNA RAS, metastatic colorectal cancer, RAS/BRAF, colorectal cancer, Patient, plasma ctDNA, HER2, Glob, Bristol-Myers, PTEN, MET, L. A. Jr., Zymeworks, ALX, F., PRA, RAS, consid-, cancer, RET, NRTK1, I.M., 5-FU, RAS WT, metastatic colorectal, FU/","##lf, 31, ##gfr, ##ection, msi - l, 94c, -, chu, ##arfin, higher, ms, gene alterations, ecd, adverse events, ##vacizumab, 271, left, 66c, mcrc, wild, e, colorectal cancer, ##6, ##it, ##dy therapy, negative, t, le, o, ##utica, p, multiple, - h, any, ##uc, cancer, first, 256, 50, ##b, mutation, . 6 %, 49, pan, w, 109c, 55, tumor, ##oint, h, 241, ##ace, lesions, ##9, gene, fu, 027, ##mark, grade 3, hyper, ##r therapy, but, ##um, 222, biomarker, testing, mfo, alterations, antib, bo, mss, mutations, 69c, ##uma, 41, ##vac, low, m, sided, ras, chemotherapy, n, 259c, •, mc, double, mfolfox6, certain, triple, dotted line, ##ovo, randomly, ##1 -, ##izumab, ##sel, ctdna, 37, pr, ##static, late, 5, – 739 730article, rev, ##ding, ##ome, oxaliplatin, folinic acid, ##eda, ct, panitu - survival, stage, extended, modified, tre, roche, 41 mss, primary, right, nr, ##r, anti - egfr, er, wt, plasma, al, alteredb, res, 299c, meta, me, ##umumab, ##umuma, / ms, cs, os, /, ##ox, anti, biomarker analysis, color, nrtk1, ##al cancer, ##ected ’, altered, fluorouraci, genetic, effect, honor, acquir, egf, egfr, bra, ##lfox, be, ##ect, ##i, ##a, take, ##ectal, monitoring, mumab, - l, ##gf, type, braf, negatively"
A (4).pdf,"patients, non-neoplastic pathology, plasma, rectal cancer, Colorectal cancer, early-stage, TIMP-1, colonic cancer, Carcinoembryonic antigen, Patients, Plasma, adenomas, samples, CRC (1), CEA, blood, Plasma tissue inhibitor of metalloproteinases-1, bowel, serum, CRC","ed timp, improved, cea, crc, 95, -, ##lati, 2. 2, rectal cancer, inhibitor, cc, odds, ., 89 %, ##ities, bowel endoscopy, ##el, u, fae, findings, ci, early, 24, co - morbidities, surgical, 30, 2650 8 %, car, ##er, department, end, 1, ida, detection, bow, 2. 0, 32, 6. 2, el, ##9, an automated analysis platform, survival, ##mark, 88, colonic cancer ( cc, department of surgical, biomarker, occult blood, cr, ce, ##cinoembryonic antigen (, 265, metalloproteinases - 1, kettegard alle, plasma tissue, univariate analysis, occult blood test, low, soluble, asc, ##c, tim, an, val, un, 30, 2650, timp - 1, screening, ##omas, ##ob, ##cinoembryonic antigen, specific, 6. 2 sol, early - stage disease, ##tal cancer, age, co - morbid, ##evat, ##ivariate, stage disease, all, more, tive rate, 8, plasma, large, aden, analysi, early detection, 6. 2 soluble, ##ble, rec, significant, re, posi, sensitivity, test, elevated, ##os, or, odds ratios, ##a, ##copy, automated, bio, colonic cancer, low positive rate, serum, low positive, ##obt, f"
A (40).pdf,"patients, ates, protectin, malignant transforma-, Colorectal cancer, gut, CRC3, colonic lesions, Cancer, lesions, stool, Fusobacterium, adenomas, QMP CRC, stools, colonic, precancerous lesion, body, polyps, intestinal, colorectal cancer, CTL, blood, enterotype, CTL patients, CRC microbiome, Bact2, colon cancer, E., cancer, L., CRC","η, crc, diabetes, ##gn, per, variables, dia, ##pe, gut, obesity, ##ora, mu, eight, n < 10, ade, ctl, χ, ci, 05, malignant, ##pies, control, under 50 years, colorectal cancer, tests, ##9art, ##osco, negative, 133, colon, excess, united states, multiple, and 10, cancer, ta, poly, 000 people, relevant, ##me, ##hea, wallis ( kw, iv, lcpm, ##marker identification, lower, bacterial, quantitative, microbiome assoc, lesions, biological, les, die, fu, approaches, chi - square (, blood pressure, ##tive, ##d, int, ##2, positive, normal, polyps, cr, shifts, six, ,, clinical, individuals, ##c, ps, rte, un, ##bial taxa, co, benjamini – hochberg method, bact2 enterotype, colonos, q, 58, absent, health status, ##ding, adenomas, ap, ct, bmi, rep, numerical, cancer progression, ##ia -, sp, ibd, 4, dental, cramer ’ s v, 14, microbial dys - studies, –, transformation, false, colon cancer, multidomain, primary, - to identify, ##iling, microbiome profiles, microbiome, ##o, ##y, microbial profiles, meta, micro, ##ctomy, metabolomic analyses, stool, interpretation, color, re, test, ##lth, covariates, high, ate, 100, body mass, three a, ##copy, multiple testing correction, kruskal, sequencing, ve index, d, 11, colonoscopy"
A (41).pdf,"patients, colorectal, BRAF, leukemia, stage IV rectal, moni-, patient, GAL-, K. Kato, Cancer, material, Colon, E.O., colorectal Y.K., C. C. Palsuledesai, Tempus Labs, line, ACT, MRD, resectable CRC, Patient, Ltd. K.O., Co, tumor DNA, Rectum, Ltd., tumors, MedicineArticle, colon cancer, stage IV CRC, AMEA, cancer, CRC","refer, ##bb, chugai, treatment, crc, 95, disease, -, personal, recur, higher, ctdna status, ms, ie, multicenter circulate - japan, 2 – 3 weeks, systemic, ##e mutation, ci, tor, 84. 33 %, 24, surgical, multiple, mrd, follow, nce, lectures, circulating, ##ur, month, dfs, ##lu, tumor, ##il, 8. 93 %, ##e, stage ii – iii res, molecular recurre, mr, multivariate, shorter, targeted therapies, ##d, ctdna monitoring, positive, may 2020, spontaneous, cr, ce, myers, act, ,, du, 33. 56, 95 %, high ppv, tumors, sur, low, ras mutations, chemotherapy, nature, 1. 9 %, 93. 20 %, 2,, lance windows, un, ##ivity, poor, recurrence, ctdna, ##tal, 06, gal - int, dan, longitudinal, ct, ate th, stage, analyses, only, extended, reliable prognostic biomarker, analy - tion, colon cancer, clearance, it, 8, 83. 20, galaxy study, plasma, nothing, det, did, pat, stage iv, guard, free survival, ##ification, 6, 240, os, ##n, rec, color, re, lower shed, clearance rate, 23 months, ##bution, honor, bra, between, 2, actionable, ##ect, v6, sy, result, po, d, surveillance, ##00, f"
A (42).pdf,"patients, microbiome, Methanobrevibacter smithii, tumor, CA261961, H. hathewayi, carcinoma, intestinal cell, left-side, gut, adenoma–carcinoma, UK, Cancer, oral, stool, colorectal adenoma, stool samples, adenoma, samples, rectum, gut microbiome, colon, oral-derived, tumors, tissue, mucosa, CRC microbiomes, cecum, cancer, ZOE Ltd, SGBs, CRC","0 – iii, crc, separation, council, stages 0 – ii, 101045015, enriched, per, 0, control participan, higher, ca, gut, intestinal cell proliferation, ##co, iii, ##055, derived, ##cinoma, mu, ##hold, proportion, progression, metagenomic study, left, colorectal adenoma, tissue invasion, ##3776, ##l, ##ational multivariate analysis of variance, u, free, 191, fees, st, screenin, 1, 471, sta, stool -, based, consultancy, colon, ##ostridia, car, fth, 645 samples, two, transverse colon, ##me, tumor, iv, right colon, ##253185, later, 1, e content, more than 250, carcinoma, su, european research, 702, mi, lower, cog microtou, institute, en, oral, cl, infiltration, to, ##9, ##j3e2w2, optimistic, ##oma –, les, ##vi, micro - n nurses ’ health study, int, but, ##gu, competing, stool samples, single, ##nding, cr, microbial, stage 0, side, 94, du, stage i, society, ##bs, 2019, tumors, on, 625, di, microorgani, ##lin, 2017, from, fi, n, ##sms, research, ##c, rice, sm, un, institutes of health, ##196, diverse, late, sg, ’ health study, 116, different, in, stages, ome, 98, stage, adenoma, higher abundance, differences, disease progression, iii – iv, erc, previ, 344, ging information control, italiana pefindings, 3, 741, ##mut, i, ##ch, ##hanob, right, 716575, ##raniye, ##ation, microbiome, er, sam, large, stage iv, meta, micro, g strategies, microbiomes, aden, 6, ##8, ##en, stool, - ples, multivariate analysis of variance, ass, met, ##fu, rectum, 2, um, right - sided, metagenome, ##biomes, ##qu, differ, ##a, 16 r, zoe ltd, ##cobiome, microbiome score, bio, ##cos, left colon"
A (43).pdf,"patients, tumor, Colorectal cancer, early-stage, cells, specimens, CRC patients, cell, DLD-1, Colorectal cancer sera, sera, Serum, fecal, human CRC tissue, CCL-228, EV, extracellular vesicles, EV fractions, EVs, human colorectal carcinoma cell lines HCT116, CCL-247, fetal bovine serum, FBS, CEA, blood, Cells, CCL-221, cancer, serum, sucrose, CRC","crc, 10, ev, dif - ferential, shotgun, eight, ., dld - 1, 107, washed, ##ose, ultracent, colorectal cancer, fetal bovine serum, fbs - free medium, human color, can - didates, cancer, ultracentrifugation, tumor, ##ectal carcinoma, hct116, expression, su, ##ports, institute, human, western, pub, c, cushion13, 29. i, up, b, targeted pro, sw620, cr, accordance, 68, ##cr, blood, fresh, 44, cell - conditioned media, ##ubator, 37 °c, supernatant, co, chiba, id, many, rpmi - 1640, ##teomics, rna, sera, −80 °c, medium, biomedical innovation, chiba university school of medicine, sw480, methods, %, high - throughput detection, 54, cells, maintained, color, ##rifugation, search, cell lines, large - scale, rc biomarker, ##al ”, volunteers, school, ##7 proteins, 2, proteins, shotgun proteomic analysis, healthy, inc, system, analysis, serum, ev fraction, 687"
A (44).pdf,"MMP7, gastrointestinal cancer, CACC, carcinoma, cancers15, UC, Colorectal cancer, SLC16A9, CXCL8, human, cancers, cancer16, intestinal, samples, TIMP1, Colitis-associated colorectal cancer, rectum, colon, sigmoid colon, ulcerative colitis, IBD patients, CRC1, cancer, CXCL1, bowel, PLAU, CRC","improved, crc, rank aggregation, ss, ca, ##tro, ##tum, ##el, ##tive colitis, fe, uc, connections, expre, colorectal cancer, hsa - mir - 194 - 5p, ib, five - year, colon, o, 15 %, cancer, severe, treatments, 147, 950 new, 1, bow, ul, hsa, lower, slc, c, int, gene co, cr, mir - 378a - 5p, systems biology, system approach, di, expression network analysis, commons, of medical, . 5 – 2. 4 times higher, associated, ##cc, om, data - cent, lower colon, of medical sciences, stages, messenger rna, – 2. 4 times higher, hub, ut, is, university, ##7, mir, disease progression, ibd, ##16a9, creative commons attrib, 53, 200, hs, experimental, inflammation, micro, deaths, medical sciences, sl, ##cera, rec, reproduction, colitis, biomarkers, - fold, ##estinal cancer, rectum, ##cerative colitis, 53, 200 deaths, hsa - mir - 378a - 5p, rra, biology, ##adan"
A (45).pdf,"patients, nonmetastatic colorectal cancer, tumor, plasma, MARCKS-like protein 1, cancer patients, patient, Colorectal cancer, L. H., gastrointestinal malignancies, tumor cells, Cancer, exosomal proteins, cell, cancers, protein kinase C, immune cells, calcium-dependent calmodulin, MARCKSL1, metastatic colorectal cancer, PKC, tumor necrosis factor, cytosol, metastatic CRC, colorectal cancer, CA19-9, exosome, cells9, metastatic lesions, EVs, extracellular vesicles, tumour DNA, serum tumor, stage II, non-small cell lung cancer, CEA, tumors, actin cytoskeleton, Exosomal, Lab Autom 21, Cancer J Clin 71, alanine, cancer, MARCKS, immune cell, metastatic colorectal, CRC","dna, ##ristoy, ##sicle, ##ectal cancer, ep, natural science foundation, small, ev, recur, ##gno, ca, gut, mcrc, protein 1, traditional chinese medicine, colorectal cancer, ‑, marcks, 185, limited, within 5 years after, ##stasis, ti, less than 20 %, alanine rich protein kinase c substrate, cancer, circulating, tumor, 3 - years, 20 %, press, my, grants, mi, circulating extracellular ve, lesions, marcksl1, ##mes, ##mark, – 45 %, ##oso, ##tokines, metastasis, cr, ce, exosomal, ##omics analysis, 5 - years, ##nclusion, pro, mc, conditions, ##c, derived noncoding, stage ii and iii, june 2023, commons, screening, ##static, cancers, lung, profiles, microfluidic exosome analysis, biopsies, ##ssibili, 4, ##oco, non, app, used, cancer transformation syndrome, i, biopsy, oncogene, ex, inflammation, meta, ##ti, marc, 36, ##sta, 15, missed, color, metastases, tiny, ##al cancer, liquid, elevated, broad - spectrum, shu, ##estinal, rnas, open, ##al, ##osomal, ##ect, proteins, ##ks, imaging examinations, university of tradi, po, ##gnancies, ultra - sensitive"
A (46).pdf,"MMP7, MF, CDC20, mast cells, Cellular, Colorectal cancer, CRC Colorectal Cancer, CLCA1, Cancer, CDK4, CDC25B, MMP1, neural network, immune cells, Z., BP, K. D., J. L., IQGAP3, colorectal cancer, CRC tissue samples, UHRF1, Cancer J. Clin, CDK1, TEAD4, F., E., H. A. DNA, TRIB3, SLC7A5, CRC","crc, rf random forest, roc receiver, bioinformatics, machine learning lasso, source, mmp, ml, e, of, next - generation se, expressed, activated mast cells, ellular component ppi, roc, 2035, machine learning methods, operator, gbm, cancer, expression omnibus, cc c, least, sv, cl, omnibus degs, ##s, normal, artificial neural network, high - throughput sequencing technologies, selection, cr, ##p, machine learning analyses, immune correlation, 2d, li, abbreviations, 2. 5 million, ##c, gene ontology, geo, - 6 1ww, genes, om, combinat, sharif, 7543, kyoto encyclopedia of genes and genomes, of technology, global, gradient boosting machine go, immune cells, rna - se, related, ##m support, university, iq, ##7, microarray, absolute shrinkage, ion, kegg, nin, gene microarrays, mf molecular function bp, 152, 810 new, science, tea, cd, vector machines ann, cdc, ##8, sl, ##ga, technology, color, ##al cancer, functional enrichment analysis, dna microarrays, ##0, 53, ##al, differentially, ##ect, ##a, cdk, gene expression, biological process, protein - protein interaction, auroc area"
A (47).pdf,"patients, GEO, ra n o n ., c g a d, NOS2, Colorectal cancer, Cancer, colon cancers, cancers, Patients, c, Cytoskeleton, c . 2 1 7 0 8, muscle cells, IRDEGs, H. E., K. D., malignant tumor, samples, colorectal cancer, metastatic CRC, Cancer J. Clin, rectal cancers5, IL-17, nitric oxide synthase 2, K-M, actin cytoskeleton, gastrointestinal tumor, CXCL2, cancer, CXCL1, ECM-receptor, CRC","treatment, cancer burden, crc, ##gs, l, tcga, 0. 1 0 3 8 / s, immune, enriched, cy, ##mun, 0, ss, ##finding, ca, mode, 10 years, colon cancers, commons attribution - noncommercial - noderivatives 4. 0, eight, regression analysis, 4. 8 %, 9. 5 %, 2 2, e, than 50 years, overlapping, tina, ##oth, nitric oxide synthase 2, 185, cxcl, significantly enriched, ecm, its, different clinical features, 9, 900 000, ##oc, eocrc, validation, year, ##era, forest map, tumor, ##toskeleton, 1, 321 degs, expression, 326, ##ea, ##rc, univ, pathways, cxcl1, gene, survival, ##d, roc curve, 7, corre, cox, 2021, biomarker, vivo, cr, six, ,, gs, 41, on, m, clinical, chemotherapy, nine, ind, nos2, low risk scores, geo, genes, many cancers, february 2025, more than 19 million, 119, hunan university of medicine, ##static, 5 - 88, late, 5, 9 8 - 0, cancers, different, enrichment, in, cxcl2, global, validation analysis, related, samples, ##in cytoskeleton, 4, 4 %, 0 8, il - 17, surgery, nos, %, meta, ##5 degs, rectal, 6, im, deaths, 36, os, cox regression analysis, 207, 11ww, march, sensitivity, hunan provincial science and technology department, tcga group, department of gastrointestinal, 3, second people ’ s hospital, september 202, decreased, tc, 2, 202, signaling pathways, ##py, high, sixty, scientific, ariate, 136, 1. 1, k -, wa"
A (48).pdf,"patients, tumor, Fig.5, LowPS HighPS Patients LowPS HighPS Patients LowPS HighPS, TGFβ, cells, stage II/III CRC specimens, applicationof, Colon, FHL3, Supplementary Fig. 1, tumor specimens, FHLproteins, HCT116 cell line, Patient, CRCColorectalcancer, HiScript III RT, stage II/III CRC patients, TGFB1, N0) 1.97 1.15−3.37, stage II/III CRC, TATCAACGGG, cancer, Rectum 91(44.8, pN2 disease, TGFBI","crc, 34 ( 32. 7 ), 0, ##gno, 0. 007, tgf, 60, basedfra, ##gt, images, rt supermix, ), 0. 0, 162, ##weretheprimersequencesusedforrt - from, well balanced, ib, p, 274 ( 82. 3 ), ##atients, ##ispl, tumor, 26, ##pl, externalvalidation, ##ction, pn2 disease, 123, pts, transfection of, ##ceiveroper, 112, 6. 1, ##ct, 3 ) 155, ##totalrnaiso, cr, 79, 81 ( 39. 7 ) 30 ( 47. 6 ) 51 ( 36. 2 ), 36. 5 ) 26, converted, chemotherapy, 55. 9, hr, published, 70, 106 ( 52. 0 ) 35 ( 55. 6 ), 1., ##discovery, 195, 62, 3. 2 ), stage, samples, lowps, sirnas, pcdh - cmv -, ##curvestop, 74, 19., forwards, ##ion, female, 71, 108, i, was, 62. 7 ), ##san, 54, ptstage, studies, 33 ( 23. 4, 63 ( 60. 6 ), 3, ##gg, no, tc, rectum, ##theint, fhl3, f, 128, asa, we, if, 33. 8 ), ., 174 ( 85. 7 ), ci, 191, ##horeceivedtreatmentat3aca, ##to, 1. 0 ) 2, ##la, ##ithstage, 2. 81 1. 33−5. 96 0. 00, 77. 0 ), 76. 6 ), 02 1. 21−3. 63, ##hort, 53 ( 84. 1 ), 0987654321s, 84 ( 41. 4 ) 37 ( 48. 1 ) 47 ( 37. 3 ), quantitative, stage ii / iii, pc, lipofectamine™ 3000 reagen, ##d, 119 ( 58. 6 ) 40 ( 51. 9 ), ab, 79. 4 ), ze, ##teomic profil, 41 ( 39. 4 ), 87 (, 90, ##dfsanalysesine, quan, - iii, value application, . 1, pro, mc, 57. 4 ), 96 1. 19−3. 22 0. 008, 60. 3 ) 33, ##ity, 63. 8 ), ##tologytype high, 85. 7 ), ##onthex - axis, axioskop - 2, ct, calib, 0. 003, 14, hc, 48, stage ii /, colorectalcancer, 58. 6 ) 65, ##udy, 38. 1 ), methods, 57, internal, ##omo, 83. 7 ), cells, complementarydna, ≥65, 40, ##ofpatient, ##tc, sol, re, ##ca, 2, high, thisst, cdna, ##du, ##trans, pt, disease, clinical routine variables, 2. 75, hiscript iii, ##oftotal, tgfb1, 20 ( 31. 7 ), 85. 6 ), free, of, t, colon, ##byusing vector ’, ##bi, 91 ( 44. 8 ) 35 ( 45. 5 ) 56 ( 44. 4 ), 9, ##survival, clone, 42, ##iss, reverse, tgfβ, ing analysis, pt1, 73, ##zy, ##anal, ##elt, 77. 8 ) 61, rt - pcr, ##of, missing, ##t, tt, qpcr, pl, his, signature, . 6 ), 97, ##asmi, low, ##ps, . 2, 2., ##c, 97 1. 15−3. 37 0. 014, academic institutions, sex, 67 ( 87. 0 ), 142 ( 42. 6 ), ##t116 cell line, 158 (, npj, 16, ##on, internalvalidation, g, ##gene, ##par, ndahalflimdomains3, ##com, ##sur, 20. 6 ), 8, 52. 4 ), 74 ( 32. 3 ), ##kitv2, specimens, 107 ( 84. 9 ), 11 (, ##reverse, 78. 1, ##ex, externalvalida, 113 ( 80. 1 ), 89, ##ach, clinicalcharacteristicso, ##anda, 7 ( 3., pnstage, and, 20. 7, systemic therapy, clinical validation, keyprotein signatures, e, 166 ( 81. 4 ), 108 ( 32. 4 ), 35. 8 ), 2. 01 1. 15−3. 52 0. 014, ##gram, forwardstcacggagatggtgatgagccaand, roc, ta, tumorlocation, validation, ##sw, va, 1, male, ##3, 1. 46−5. 17, 99 ( 43. 2, 53 ( 37. 6 ), ##ds, ##tom, ##the, ##probability, ##w, ##jacentnormalcolorectalmucosafrom60patients pnstage, 138 ( 41. 4 ) 39 ( 37. 5 ), . 7, . 0, 13, n, pt2, 260, ps, transient, < 65, ##otted, 2 ), proteomic profiling, 95 %, 5, in, (, ##pse, ##iate, 7 ( 11. 1 ), ##and, 74., ##m, ##omics, 1. 38−4. 96, ##df, ##withtheremarkguidelinesfortumormarker ps, 740, 98 ( 48. 0 ) 28 ( 44. 4 ) 70 ( 49. 6 ), ##yzedacohort, pt4findings, label - free intensity - based, ##demiccenters, training, ##ship, rec, 187, 67. 7, 171, 101 ( 44. 1, ##fect, afastpurecell / tissue, 0. 002, ##tage, ##lation, 62. 5 ) 130 ( 56. 8, highps"
A (49).pdf,"urine, liver, neutrophil elastase, Tissue, Fabrice@mayo.edu, human, stool-derived EVs, Extracellular vesicles, stool, secretin, cellular, USA.3Departmentof, NETs, bacterial- derived proteins, stool EV, pancreatic juice, esophagus, visithttp://creativecommons.org/licenses/by/4.0/., SD):10kDa:19.37%±12.00,30kDa:19.53%±10.86,50kDa:18.70%±8.56, radish, SEC, ELANE, colon, spleen-derived, blood, neutrophil, C, resultsin, lipids, small intestine","size, -, ##hatcans, ##gno, ##filtration, ##oscope, ##valida, ##down, ##evsincrc, ##hat, ##divisionofgastroenterology, concentrate, basedcm, ##rnapost, onevreco, proteomics, super, for, cow, pig, potato, radish, almond, thesefindingsdemon, receives, spleen - derived, ##ind, indicating, stool supernatant, ##meta - evsb, ##analysis, ##er, ##cent, ##competing, orange, ##opa, ##dis, ##used, ##ments, ##ons, human, to, bystatutoryregulationorexceedsthe, ##ular, 16. 05, clinicalcharacteristic, but, ##so, withalargersamples, ##needtodevel, bo, centrifugedat2000×g, cr, ##ted inventor, ##yourintendeduse, ##ep, ##ont, lipids, ##vid, individuals, ##ran, ##concentration, ##r ’ srecommendationuntilthe, ##ain, ##find -, ##×, small intest, ##4000×gperthemanufa, clinic institutional review board, ##ome, removeanycellulardebristhatwasnotremovedduringinitial, ##fo, ##agepercentvesicular, proteomicdatasupport, several, ##materialint, samples, ##con, nets, ##pernatant, ##ified, ##scriptomicanalysis, additionalinformation, ##fuged, was, ##prior, ##te, littletonovariationwasob, ##ofastool, ##her, ##gh, ##omes, dynamic, ##cts, ##ofsto, stoolsu, exclusion, volume, fraction, ##nucleica, secretin, ##coming, proteins, ##acomprehensive, ##outsidethevesicles, ##cter, ##rnaamo, 10, ##at, at, we, if, . 53 % ±10. 86, 50k, ##toolstoint, ##co, ##tech, derived, ., ##21, ##tractwiththelargemajority, ##olume, ##forisolationofstool - composition, ##streamapplica, size - communicationsbiology, ##sic, ##avariety, ##hil elastase, . 18, ##to, ##valuated, supplementarymaterial, ##var, 228, api, ##ava, complex, end, ##pro, waspassedthroughthe, ##13, ##hort, ##non, ##rea, ultrafiltration centrifugal, lower, ##ting, allotherauthorsdeclaren, el, ##aratee, ##d, ##bilayerandc, ##olevproteome, ', ##methodbasedon, all three domains, ##lar, ##earcha, neut, ##contentofcolon -, protein, ##stratethatultrafiltration, ##separa, ##limport, ##frame, youwillneedto, ##thecopy, enzymatictreatmentrang, . 29 %, ##ted, ##tm, licensed, ##previous, ##purity, ##atic juice, ##min, ##aver, following sec complexes ( rnps ), ##tose, ##with, und, ##work, ##k, consumptionandderivedfromchi, ##mwcoa, ##forfutures, ##vera, ##massspectrometryexperime, ##inas, ##prote, stool - derived, ##cture, density gradient centrifu, ##tions, ##permissiondirectlyfrom, ##due, ##per, ##vr, 202, techniquesuchasultrafiltratio, ##reative, ##be, ##les, ##may, ##stic, forth, ##he, ##fromevs, fluid, ##line, ##islikely, mass spectrom, consensus molecular subtype, the, u, ##not, ##rem, ##uo, ##notincludeat, ti, ##andca24, ##differ, our, ##sforpatientsinthelarger, ##ese, pan, ##ilable, ultrafiltration, ##of, ##rial, wedonotrecommendtheuse, ##combinationof extracellular vesicles, sc, ##iomark, ##fluen, ##nalytical, phospholipid, ##proces, 2d, ##ov, ##patientswere, ##leprotein, therefore, colon, liver, esophagus, derivedev, from, ##na, ##omic, buffer solution, ##ol, supernatant, results, evs, transcriptomicprofilingofcrchasledt, ##ful, ##rop, cellular traps, ##ies, ##gesamplev, betweenmwc, ##oft, ##yougiveappropriatec, ##andrecoveryparameter, 37 %, ##thecombinationof trointestinal, optimal, ##greementbetween, 63, sec, ##versioncontains, ##ub, humanbody, ##wedonotanticipateadifferentoutcome, ##isolationto ingsthatwillserveas, sponsored, supplementaryinformation, ##par, uf - 100kda, ##ole, as, mass spectromet, ##ition, ##ultra -, stool, ##80°, ##swithhighsensit, contamination, ##id, ##potentialofstool - derived, ##nat, wei, filters, given, ##ach, continuouslyaspiratedfromth, myelo - uncoverthehumanandbacterialproteomeofstool - derivedevsisolated, 3d, ##f - 100kda, differential centrifu, thee, ##s17., which, ev, ##pe, and, ##vb, ##43 %, ##vis, ##tion, ##8 %, 100kda, ##vsfromsoluble, , 000, derivedevshavenotbeenwell, ##tha, e, mw, ##his nihgrantsca214679, ##inate, o, ##amp, ##ertodisruptrnpsanddigestanyrna, ina, ##ant, this, ##sicular, stooliscomprisedofw, ##att, visit, derivedevsorig, 1, ##are, ##errogate the, ##dd, ##fr, ##very, ##ige, extent, norultracentrifugation, ##tom, ##lite, wetreatedevfrac - becauseitwouldlikelyresultint, ##ri, ##can, ##the, cms, ##ffe, ##ofthes, ##cefficiently, ##whichroyalt, ##in, ve, ##commonslicence, tissue annotation, ##di, ##ima, 30, ##puri, ##ev, ##lipoprotein, 10http, ##biopsy, ed, ##fm, in, ##proteomicsstudies, (, ##othe, 10min, chromatography, these, ##pre - analytical, ##fromthe, ##and, 4, iables, ##m, ##ums, ty, 100k, prote, ##severalkeycompone, ##etry - based, fewstudieshaveinvestigated, ##res, study, ##gfor3, ##is, ##niquest, ##ci, . 70 %, ##byexactsciences, most, ##ce, classification, obtain, ##usion, ##methodswithproteinasekandrnasea filtrationmolecularweightcut - off, ##pa, of life, ##mal, ##ther, ##fu, ##viewacopy, food speedvacuumtoconcentrates"
A (5).pdf,"TW, patients, early-stage CRC, stool DNA, plasma, CNDP1, DDA, matrix, carnosine dipeptidase 1, leucine, CEA) [, TF, DNA plasma, patient, carbon, Colorectal cancer, early-stage, alpha-1-acid glycoprotein 1, Septin 9, Human samples, CA125, LRG1, IGFBP2, pancreas, CRC patients, A liquid biopsy, NPV, stool syndecan2, Plasma, CRC [, line, LDT, CA242, SERPINA1, ORM1, insulin-like growth factor binding protein 2, serpin, Huang Q, Serum CEA, serum NSE, benign polyps, fecal, liver cancer, publi, LL, colorectal cancer, CA19-9, Peripheral venous, APC, Br J Cancer, plasma samples, ITIH3, FIT, colorectal-cancer, inter-alpha-trypsin inhibitor
heavy chain 3, CEA, DNA, blood, PXD042639, CRC plasma, seven-protein, FG, cancer, PXD042652, DIA, ple, C9, cial, cancer-, CA724, CRC","dna, cea, crc, l, ca12, ca19 - 9, 95, seven - protein cla, locked, ##mete, 0, ##he, dia, hundreds of peptides, dd, ca, fixed cut, cndp1, alpha - 2 - glycoprotein 1, cn, auc, methyl, rs, pro - tein, epi procolon test, 11. nakamura, septin, colorectal cancer, negative, based, plasma samples, ##ates, dyna, p, blood sampconcl, multiple, multi - reaction monitoring, ti, two, ##cy, col - specificity, assay, panel, cancer, ##2 level, 73. 8 %, complement c9, blood tests, multi, improvement, 0. 905, mutation, pan, regulated, npv, liver, regression, mrm, gene methylation, window, my, fit, benign, quantitative, ##5, mdg values, human, ##t, mr, fo, translational medicine, ##mark, au, up, peptide sequences, 88, types, ##ych, labo, testing, biomarker, endent, september 2020, ld, cr, reproduction in, ssifier, ,, 92. 3 %, apc, blood, ##pina, 905, ##chang, 13, clinical, dna testing, protein, blood test, ind, ##c, average, ser, ca724, septin 9, serpin family a member 1, carnosine dipeptidase 1, machine learn -, ##creas, inter - alpha - trypsin inhibitor heavy chain 3, features, chinese, specific, hospitals, stages, 2 years prior, ##rd, stage, ca24, samples, : 188 page 7, ##usions, deposited, mass spectrometry background, ##m, alpha - 1 - acid glycoprotein 1, leucine rich, ##on, down, und, non, est, –, ##ated dna, quantify, i, biopsy, bmp3 / ndrg4, it, biomark, early -, invasive, insulin - like growth factor binding protein 2, ia, plasma, did, ##y, locked logistic, carbon nano - tubes, 909, ##ay, 87 %, creative commons attribution 4. 0, plasma proteome, thi, peripheral, the per, stool, dda, color, ##al cancer, col, proteomic analysis, liquid, han, or, translational potent, improving, mass spectrometric data, open, z, ##al, ca19, 2, ##ect, stool syndecan2 methylation test, proteins, k, , adaptation, distribution, healthy, ##psy, variation, mass spectrometry, ##gf, regulation, bio, imperial, serum, ##obt, f"
A (50).pdf,"colorectal, malignant cancer [3], Cancer Cell Int, anti-cancer, Colorectal cancer, Ha D, gests, gastrointestinal tract, cancers, Sci, bladder organoid, Kim D, line, Wu Q, stage III colon cancer, Verrill C, adenoma, Rep., Shin K, colorectal cancer, samples, Linder N,, lncRNA LINC00974, portal, tissue, cancer, stage-specific, sug-, CRC","crc, -, declines, lnc, commons licen, decreas, ., commons licence, network, u, medicine, center, st, early, colorectal cancer, five - year, ##oma, ##00974, t, de - mirnas, cancer, year, colorectal, 147, 950 new, mali, 1, significantly, using deep learning, 37 degs, au, ##can, his, 90 to 40 %, sci, de, cr, 90, malignant cancer, bladder organoid models, ##ous - stage, pre, intelligence, . 0, gas, rr, ##c, th, ##adan university of medical, lin, of medical, adenoma,, 200, artificial intelligence, ed, machine learning, cancers, multice, based sciences, gma, stage, adenoma, nter study, ##cer, systems, deep learning based, 53, 200, five, anti - cancer drufind, ##bution 4. 0, aden, origin, im, 950, gastrointestinal tract, 40 %, ##sts, ##trointestinal tract, ge, 53, 20, 147, retrospective, de - lncrna, ##i, stage adenoma, commons at, analysis, artificial, ##gnant cancer"
A (6).pdf,"B cell, STXBP6, breast cancer, plasma, trans pQTLs, fur-, GREM1, CSAG1, osteo-, single-cell, colon tumor tissue, rectal cancer, FUT3, Colorectal cancer, B, epithelial cells, cells, UK, human, monocytes, cell, cancers, CD86, ADPGK, CHRDL2, TIMP2, line, CXADR, pancreatic cancer, T cells, cell-type, Log 2 FC, fibroblasts, urothelial cancer, colorectal cancer, POLR2F, sup-, tissue stem cells, SMR locus, colon, colon tumor tissue cell, monocyte, Joint, CLSTN3, tissue, colon cancer, cancer, endothelial cells, adipose tissue [, teome-wide, MMP2, teins, CRC","l, 10, interactive pairs of proteins, rigorous analyses, ##words, ep, nature science, enriched, mr design, 0, ur, therapeutic drugs, obesity, summary, ., fut3, calization analysis, urce, 12, mmp2, > 0. 5, screening b, the, class, 05, log 2 fc >, two proteins, avail - of 13, den, meta - analysis, 09, t, colon, te, multiple, two, gability evaluation, cancer, pro - color, committee, our, cell expression, f, fur, bay, tumor, 1, not, gr, expression, , proteome - wide, mi, . 4 %, pathways, ma, biol, heidi test, levels, ing, cl, protein - s12 – s, mr, fu, measured, c, ##mark, failed, ##d, able, ##st, plasma proteins, natural science fund, normal, utic drugs, leveraged, single, pol, cr, eli, six, ##t3, ##rape, commons attribution 4. 0 international, ##ra, plots, ##in, mg, tissue, 13, 13 proteins, seven, timp2, protein, cd86, ectal cancer, ##c, tim, th, an, sm, heidi, malig - teome -, pp, ##mune, replication, screening, insufficient, drug, ##delian random, ##tal, genetic instruments, open access reso, cod, ch, enrichment, them, stage, 1. 9 million new cases, ##ian randomization, plas, - evidence, 0. 05 level, est, g, lia, colon cancer, finngen, 0. 9 million, csa, study, five, cell ‑ type specificity, plasma, four, 15 : 75 page 2 of 13, men, rectal, cells, cs, ##ithelial, deaths, human protein atlas, young scholars, random, distinguished, fide, tion, ##tl, studies, instruments, trans pq, ##em1, rec, trans p, color, smr, col, protein - coding genes, ##q, elevated, trans, heidi tests, epide - of, biomarkers, clstn, decreased, ##ie, coding genes, 2, ##rdl, k, proteins, clas -, et, ##qtl, type, plasma protein, ##ian randomiza - mary, ##xadr, 11, ##em"
A (7).pdf,"K.D.;Jemal, five-protein, P.;Wilson, Sixofthe27proteinmarkersweresignificantlyassociatedwithCRCriskin, MDPI, body [, F.Globalpatternsandtrendsincolorectalcancer, F.R.;Karin, CRC","thee, written, ##sight, ##ssmento, ##de, ##candmayfa, ##he, ##asse, ##roved, - like, ##tudya, ##pop, ##rolesofobesity, ##jun, new, ##tion, ##oftheseprotein, ##playersfornearlyallessential, odds, ##kines, ##tet, ##tum, ##xi, etiologyofcrcandmayfacilitat, ##ysesshowedconsistentassociationsforallproteinswiththeexclusionofcases, ##sintothetumormicroenvir, cytok, ##arecriticalplayersfornearly, iss, the, for, with, involved, ##ft, ##fied, ##hein, ##withcrcriskinbothdiscoveryand, ##asesan, ’ shealth, ##ec, ##1. 9million, ##onment, ##patternsand, like, ##ology, 09, ##alle, ##isticrolesofobesity, multiple, ##to, ##processes, ti, restricted, ##biomarkers, ##1. 54, ##hand1. 88, circulating, this, cancer, informed, ##colorectal, ##ing, ##mechanistic, our, ##ava, ##hecreativecommons at, ##me, ##att, ##ctor, ##pro, ##tein, 1, ##are, institutional, ##app, ##ofcirculatingproteinsasriskfactorsorbiomarkersfor, ##toproteinsforwhichextensi, ##ons, ##zing, ##itical, ##ffiveproteinmarkers 1 -, ##play, largely, globally, ##of, ##2022, ##alsolinkedproteins, am, matrix - de, chemo, ##orwhic, ##crcandm, ##d, ##e2022, ##st, ##lta4, int, ##by, ##timate, ##the, ##can, ##ulin, ##cancer, ##ila, ##sin, conflicts, cr, ##p, ##totherapidriseof, ##da, ##ins, ##mation, ##forcr, ##cr, increase, ##appro, ##ns, coldsp, ##ep, ##proteinmarkerswer, ##processesint, ##date, ##fully, ##ofproteinsinthehumanbody, ##aths, ##orth, ##pp, ##pot, 27, ##vid, sd, ##di, ##validationsets, conditions, restrictedtoproteinsf, ##cd, ##wc, 30, ##tee, ’ shea, isthethird, ##low, previous, published, five - protein score, ##fa, ##bynih, ##approximately1. 9million, ##mapsand, ##ulation -, thedatapresentedinth, ford, ##claim, 06, ##ob, ##ath, cancers, ##ofci, ##ducted, ##oft, ##grad, ##cilita, ##sinto, ##was, ##case, inresponsetosystemicinflam, ##priorknowledgeofthemechanisticpath, ##ear, ##dt, ##ive, ##ju, ##int, ##facultyofdentalmed, ##cer, ##con, ##achemployedinthosestudiesis, ##21july, ##ub, ##and, ##vel, nest, ##as, ##30, ##ands, ##biological, ##with, ##mate, ##matedt, ##bu, circulatingpro, apaneloffiveproteinmarkers, 71, colorectalcan, ##com, ##flam, ##hattheglobalcrcburdenwillincrease, ##60 %, inresponsetosystemicinfl, ##neat iwatemedicaluniversity, ##newcasesand, . 9, colorectalcancer, it, ##res, ##eth, ##he27, apanelo, idenovelinsightsintothe, ##sulinandi, ##withcrcr, ##udy, ##fl, ##va, ##obe, ##guide, controlstu, 22, ##ti, ##mill, . 9millionne, ##ay, ether, ##mo, ##ways, dateofapp, ##population -, ##proteinsasriskfactorsorbiomark, ##idenovelin, ##ble, studies, ##growth, 10of11, ##tomaj, color, ##findingsprov, ##ly, sensitivity, 3, ##ca, ##0. 9million, ##ond, or, ##1, itises, mdpistaysneutral standarddeviation, ##fu, basedstudiesreportedsignificantassociationsofcirculatingproteins, 2, ##ight, ##table, ##dateapproachemployedinthosestudiesis, proteins, ##lev, inthed, shanghai, matrix - degrading, ##cis, ##tutionalaffil - ia, ##ectal, ##ulinres, ##sf, ##nal, ##casesand, proteinarray, ##sulinandinsulin, inverse, ##patient, ##cilitatetherisk"
A (8).pdf,"T., C.M.;Simon, R.;Bokemeyer, MDPI, Thisarticleisanopenaccessarticle, The3-BiomarkerClassifier, FrankA.Simmen, creativecommons.org/licenses/by/, stabilityandinstabilityusedtorecommendadjuvanttherapy(asproposedintheGerman, S.A.Molecularstagingofnodenegativepatientswithcolorectalcancer","-, ##de, ##ug, ##torecommendadjuvanttherapy, ##color, ##ind, ##nswerthe, ##analysis, ##23, ##er, ##uicc, ##dis, ##pati, tn, ##ve, ##ult, ##dal, h, ##patientsandsuggest, ##used, ##ng, ##mark, ##dnospecific, cr, ##fyh, ##tability, ##dadju, ##lea, ##death, ##topredict, nature, ##based attribution, ##colorectalcarcinoma, ##scoremight, ##commons, ##183223, identifyinghi, 1791, rna, ##meter, related, ##veasa, ##has, ##ras, ##vant, ##bution (, ##alcarcinoma, ##vivalcurves predicting, ##te, more, ##cre, ##her, ##igh, ##16183223, molecularstagin, ##sco, ##ura, ##mo, ##imi, ##makinganda, ##36, ##red, ##omcolorectalcarcinoma, , 3223, ##ect, ##stageiandiiwilldevelopmetastase, ##ectal, ##tre, ##tu, ##wer, ##core, ##ed, ##carcino, ##at, ##ove, if, ##jun, ##dtoimprovedsurvivalrates, ##eadingcausesofcancer, ##revealedthat, ##allsurvival, ##nc, ##vival, ##edmoreaggressivetreatm, ##ofw, ##ghtimpro, score, ##betweenmicrosatelli, ##to, 67, ##utation, ##bet, ##tsu, ##accessarticle, severalnew, ##sartic, ##based at, ##beabletobetterdiscriminate, am, ##veale, ##alcar, ##deathsworldwid, ##weenmicrosatellite stability, ##cino, ##open, ##uses, ##ise, insights, ##cr, ##isanopenacces, relateddeathi, ##hone, outcomes, ##cerafterliver, ##30 %, ##cc, ##isan, ki, ##cinomas, ##eadingcauses, ##immunohistochemistry, ##ath, them, ##patientssuffering, ##mini, only, ##uffer, ##as, ##with, ##us, iso, ##qua, ##withdis, risk, ##ment, ##oftissuemicroar, ##ative, ##v, ##ved, ##art, classical, ##per, ##asatoolt, ##dana, 2, ##low - andhigh - risk, ##incrcs, ##para, ##swasusedtodetec, ##be, ##may, ##from, ##ges, ##si, ##he, ##val, ##ss, ##isanopenaccessarticle, ##by ) license, ##ually, ##dy, ##vanttreatment, ##lt, ##mu, the, ##32, ##intomo, ##not, colorectalcarcinoma, ##redict, ##rank, ##1618, 9, ##ing, ##vedecision, ##ase, ##test, ##of, ##mi, ##t, western, ##class, ##16, his, ##group, ##ith, from, poole, an, ##10, ##nation, ##ents, bindingmotif, ##ne, ##for, cancers, ##erve, ##oft, ##was, 935, 000estimated, stability, ##hed, ##ris, 2of10 areas, ##apyalgorithms, ##re, 22se, ##bu, , prog, ##com, ##ccsta, ##cm, ##personalized, as, ##tore, ##ltivariate, ##colorect, ##malmediansurvi, relatedde, ##sta, ##gor, ##dee, ##ex, ##ha, ##ofcancer, ##ivar, ##al, ours, differentintensities, ah, ##le, ##anda, question, which, ##wil, and, go, ##patientsw, ##mas, ##remight, ##ft, sim, rb, any, this, ##eta, ##apyal, ##sw, ##edsecondregard, ##low -, ##3, institutional, ##over, ##lecularmarkers, ##om, ##1832, ##top, ##ds, easatool, ad, ##bee, ##by, ##imination, 1791patient, ##vanttherapy, ##ray, ##wai, ##icle, ##lbenefitfromadjuvant, ##men, ##in, ##adjuvant, ##urvi, ##media, conditions, license, ##bility, ##den, isa, ##ms, ##se, ##formedandsur, top, in, ##hpati, ##tooltop, ##ectalcarcino, ##hic, effectofkrasandbrafmutationsonsurvivalofmetastaticcolor, ##iate, ##ju, ##patientsandsuggest academiced, ##nti, ##and, ##m, ##cans, ##rt, andhigh - risk, md, ##is, nos, ##ad, theme, ##patientsan, ##op, who, are, color, ##grants, ##xa, ##ther, ##patient"
A (9).pdf,"patients, ZG, TZ, JinL, Colorectal cancer, gut, human, stool, Fusobacterium, LTF, 16S rRNA, malignancies, tumor cell, fecal, colorectal cancer, MMP9, CRC (1, 2, FrontiersinImmunology, FrontiersinImmunology 11, Toll-like receptor 4, CAT, colorectalcancer, CRC, RBP4","##betweengut, microorganisms, =, crc, ##met, ##ectal cancer, immune, -, natural science foundation, frontiersinimmunology, ##de, ##ponding, 16s rrna sequencing, ##lobin, ##gno, stool pro, ##he, ##pe, ##pan, and, immune - related proteins, toll - like receptor 4, hematological, ##ssi, ##tion, tumor marke, ##ofcolor, rs, differentdietaryhabitspro, protein expression levels, ##rve, ##omtheuniversity, ##l, ##treatmentareeffectivemeans, fe, materials, u, the, ##ato, experiments, alisti, markers, ##tha, mmp, early, colorectal cancer, conflict, of, immunity, offeca, ##biomarker, combination, ##eca, diet, ##projectofanhuiprovince, ##up, stool proteins, ##to, materials and methods, ##ser, ##protein, positive correlation, ##er, this, ##canbeus, ##creen, ##vince, ##marker, multi, ##bet, ##resultsdifferentfromthoseoft, tumor, interest, ##dis, ##ium, ##hort, ##pes, 1, ##pl, hospital of, ##e, ##cal, ##fr, 1126217, multicenterstudy, ##gnosis, ##om, ##ntral, ##of, ##ndingfromtheuniversity, ##nowled, ##sam, ##fe, ##stabs, ##6217, ##bee, ##mark, 112, ##es, able, 436plausible, ##foundtobesuperiortoh, ab, rbp, ##by, bengbu medical college, ##the, ##correlation, crc - enriched micro, ##l immune - related proteins, ##au, ##67, ##emog, ##nding, cr, ##weengut, improve, ##gnosticsensitivity, ##huipro, avail, ##cr, ##pina, ali, according, on, fusobacterium, ##lea, ihc, pro, ##duced, ##pot, ##di, research, ##sms, frontiers, th, an, ##inn, ##tee, ##uld, un, ##relation, in vivo, spearman correlation analysis, ##dha, . vitro, ##ted, biomarker panel, ##for, ed, speciespromotetheg, we, different, ##oft, ##ome, in, ##aregeneraofpathogenic, abundance, ##softumorimmune - related, ##ac, depth, ##eda, ##andspecificityofthese markers, clinical studies, ##organi, these, ##con, lass, ##ofthese markers, ##dietaryhabitsproducedresultsdifferent, ##fromthe, ##and, ##ands, ##as, ##bed, ##toacknowledgetothecent, ##thefo, ##bu, 14, hc, ##ignificantlyhigherincrctissuethaninnor, ##ute, ##bili, ##edanovel, hem, ##shrinkageandselectionoperator, ##te, more, ##teome, fecal immune - related proteins, biomark, 16s rrna, ##inimmunology, five, ##thes, fuso, approved, bacteria, ##bacteria, ##fferential, ##is, er, methods, discovery, ##ote, e - relatedproteins, hz, related proteins, project, 6, ##omic studies, ##fferencesanddifferences, stool, ##sti, among, immun, ##hui, j, ac, ##oe, butt, college, ##pportedpar, ##vet, ##explorethedetailed, health, ##row, ##would, han, ##like, ##tectionand, occult, ##pportedpartly, ##ject, ##fu, collaborative, lt, supervised, off, 2, ##ab, 2. 1, ##tp, ##crcinboth, proteins, inthed, ##fecalproteins, identifyhumanimmune - relatedproteinsinstoolthatcouldbeused stool, han wewouldliketoacknowledget, affiliated hospital of bengb, ##areneeded, ##biomarkerpanelwas, sequencing, ##canbe, north, po, ##tu, ##wer, bio, ##form, ##ed, 11, colonoscopy, ##th"
